



Hôpital général juif
Jewish General Hospital



McGill

DEPARTMENT OF MEDICINE

ANNUAL REPORT

January 1 - December 31, 2015

**Submitted by
Dr. Ernesto L. Schiffrin
Physician-in-Chief**

DEPARTMENT OF MEDICINE - JEWISH GENERAL HOSPITAL

January 1 - December 31, 2015

TABLE OF CONTENTS

- 1. ACADEMIC HIGHLIGHTS / OBJECTIVE AND PRIORITIES**
- 2. GRAND MEDICAL ROUNDS & INVITED SPEAKERS**
- 3. UNDERGRADUATE AND POSTGRADUATE TEACHING REPORTS**
- 4. EXTERNAL RESEARCH GRANTS & AWARDS**
- 5. NEW HONORS, AWARDS AND APPOINTMENTS
(SEE APPENDIX A)**
- 6. PUBLICATIONS**
- 7. APPENDIX A. DIVISIONAL REPORTS**
 - 1. Division of Allergy and Clinical Immunology**
 - 2. Division of Cardiology**
 - 3. Division of Dermatology**
 - 4. Division of Endocrinology**
 - 5. Division of Gastroenterology**
 - 6. Division of Geriatric Medicine**
 - 7. Division of Hematology-Oncology**
 - 8. Division of Infectious Diseases**
 - 9. Division of Internal Medicine**
 - 10. Division of Medical Biochemistry**
 - 11. Division of Nephrology**
 - 12. Pulmonary Division**
 - 13. Division of Rheumatology**
 - 14. Division of Clinical Epidemiology**

1. ACADEMIC HIGHLIGHTS / OBJECTIVE AND PRIORITIES

1.1 ACADEMIC HIGHLIGHTS

I. Introduction

The Department continues to provide excellent clinical care and teaching as well as carry out substantial translational, clinical and epidemiological research that attracts new recruits to the JGH. Although recruitment is limited by government restrictions of the “effectifs médicaux”, we have managed to recruit during the year January 1 to December 31 four full-time members and nine associate members. Potential and confirmed GFT-H recruits as well as changes in staffing are listed below.

Our research activities have been supported by both external funding agencies and by our own Clinical Research Awards.

The progress and challenges of the Department during this last academic year are summarized below.

II. Milestones

A. Recruits

The following physicians have been recruited in 2015 into the Department:

GFT members:

Cardiology - Dr. Michael Goldfarb (July 2017)
Geriatric Medicine - Dr. Olivier Beauchet (August 2015) Professeur Sélectionné
Geriatric Medicine - Dr. Dan Liberman (September 2016)
Medical Biochemistry - Dr. Michael Chen (July 2017)
Pulmonary - Dr. Deborah Assayag (October 2015)
Hematology - Dr. François Mercier (July 2016)
Hematology - Dr. Johnathan Mack (July 2017)

Associate members:

Cardiology - Dr. Nicolo Piazza (January 2015)
Internal Medicine - Dr. Nessrine Sabri (July 1, 2015)
Internal Medicine - Dr. Maral Koolian (September 2015 - August 2016) Replacement
Medical Genetics - Dr. Eva Deutsch-Andermann (January 2015)
Medical Genetics - Dr. Serge B. Melançon (January 2015)
Medical Genetics - Dr. Laura J. Russel (January 2015)
Nephrology - Dr. Nathalie Ng Cheong (August 2015)

B. Changes of Status

Medical Genetics - The Division was abolished in 2015. It has now become a Department.

In memoriam:

Division of Cardiology - Harold Zvy Pomerantz, MD, FRCPC, passed away on August 26, 2015 at age 92. Dr Pomerantz was a pioneer in clinical and academic cardiology. In his early career in the 1950's he published some of the original manuscripts dealing with the relationship between coronary artery disease and cholesterol, sex steroids and other physiological characteristics, as well as clotting mechanisms. Several of these concepts are still used in contemporary cardiology practice.

C. Promotions

Dr. Sarit Assouline was promoted to Associate Professor in December 2014. Dr. Assouline's research interest is in the development of new drugs for the treatment of leukemia and lymphoma.

Dr. Marie Hudson was promoted to Associate Professor with tenure. Dr. Hudson's research is in the area of rheumatology, with a focus on scleroderma and Systemic Autoimmune Rheumatic Disease (SARD).

Dr. Lawrence Rudski, Chief of the Cardiology Division, was promoted to Full Professor. Dr. Rudski is nationally and internationally recognized as a leader in echocardiography, with a focus on the echocardiographic assessment of the right heart.

Dr. Robin Cohen was promoted to Full Professor. Dr. Cohen's research is aimed at providing the evidence base for optimizing the quality of life in persons near the end of life.

Dr. Andrew Mouland was promoted to Full Professor. Dr. Mouland is an internationally recognized scientist in the field of HIV-1 RNA and cell biology. His research is focused on elucidating the mechanisms by which HIV-1 virus can take over the host cellular machinery.

III. Clinical Activities

- 1) Pavilion K move took place in January 2016. Patients were relocated on January 24. Medical Clinical Teaching Units (7w) and (7NW) are relocated to K6 and K7 respectively. Each ward has 32 beds (3 high intensity beds). The move occurred very fast, very efficiently and without any problems.
- 2) The high intensity bed criteria will eventually include telemetry but not non-invasive respiratory support.
- 3) Medicine patient census in ER awaiting admission is stable, with occasional peaks. Typical numbers include 10 patients >24 hrs and 5 Patients >48 hrs. However, on occasion, there are up to 30 patients admitted to Internal Medicine waiting for a bed at one time, which puts a lot of pressure on Internal Medicine attendings and residents manning the ER CTU.
- 4) More attention is now being turned to the rest of the hospital. Pathology and Microbiology laboratory have been renovated. A new integrated dialysis unit is currently under construction. A new OPAT (Out-patient antibiotic therapy unit) will be created in the former space of the Pavilion G dialysis unit.
- 5) Divisional Directors have received feedback from the administration following the Program Evaluations and Prioritization Committee initiative. It is still not clear what will come out of this process.
- 6) Pavilion K houses the new and improved Medical Day Hospital. We are in the process of developing a rapid access diagnostic and therapeutic unit for outpatients in order to manage patients who might otherwise end up being admitted through the ER. The mission will include a concerted effort to meet some of the perpetual unmet clinical needs at the JGH. Primarily, the goal is to secure timely access to procedures and imaging for ambulatory patients thereby eliminated the practice of sending these patients to the ER, as well as providing treatments such as pleural and abdominal taps or transfusions as well as pheresis. The vision is to have this referral clinic staffed by physicians (primarily internists) who will vet the consults and ensure proper prioritization of the referrals.

The clinical activities of the individual Divisions are summarized in the attached Divisional reports.

IV. Teaching Activities

The Department continues its role in the teaching of both undergraduate medical students and resident physicians in general medicine and the subspecialties. Our members' dedication to teaching is well known and much appreciated by both medical students and residents. The Department is grateful to Dr. Ruxandra Bunea, Dr. Rubin Becker and Dr. Natalie Saad for their excellent contribution to our postgraduate and undergraduate teaching programs.

In 2015-2016 we recruited into our teaching program 14 R3, 14 R2, and 14 R1 housestaff and 9 other program R1 residents. There are two Chief Residents, Dr. Daniel Blum and Dr. Arif Awan (July 2015-June 2016). Detailed reports of the undergraduate and postgraduate teaching are included below.

Grand Rounds: Of the 33 Grand Rounds given by the Department from January 1 to December 31, 2015 sixteen (16) featured speakers from outside the JGH, of whom nine (11) were from outside Quebec (see attached list).

Divisional Rounds: In addition to the above each Division manages its own teaching and research rounds as summarized in the attached reports.

V. Honours, awards and prizes

Within the Department, the following staff and residents received awards:

Dr. Ernesto L. Schiffrin received the CSCI 2015 Distinguished Scientist Lecture and Award, one of the most prestigious honors bestowed by the Canadian Society for Clinical Research (CSCI), for his significant contributions to new knowledge, his expertise, innovation and research endeavors in hypertension. As the winner of the 2015 Distinguished Scientist Lecture and Award, Dr. Schiffrin presented on aspects of his research at the 2015 Annual CSCI congress in Toronto.

Dr. Ernesto L. Schiffrin received a seven-year Foundation grant funded by CIHR from its first live pilot foundation scheme for his research project entitled "Vascular remodeling in hypertension and cardiometabolic disease: from mice to humans" as Principal Investigator starting July 1, 2015 ending June 30, 2022 for a total amount of \$3,164,111.

Dr. Susan R. Kahn also received a seven-year Foundation grant funded by CIHR for her research project entitled "Improving long-term outcomes after venous thromboembolism (VTE)" as Principal Investigator starting July 1, 2015 ending June 30, 2022 for a total amount of \$2,050,824.

Dr. Michelle Elizov was honoured as the Osler Fellow to the class of 2017

The Canadian Society of Endocrinology and metabolism selected **Dr. Brent Richards** as the recipient of the 2014 Dr. Jody Ginsberg Young Investigator Award for having demonstrated excellence as an independent investigator in clinical science. **Dr. Brent Richards** was also appointed a William Dawson Scholar for a five-year term starting May 2015. The award recognizes a scholar developing into an outstanding and original researcher of world-class caliber.

The 2015 Award for Excellence in Basic Research was presented to **Dr. William Foulkes**, Head of the Cancer Genetics Laboratory at the LDI and Director of the Program in Cancer Genetics at McGill University. Dr. Foulkes is working toward a deeper understanding of the hereditary components of cancer and of those genes that predispose individuals to developing cancer.

The 2015 Jewish General Hospital Award for **Medical Excellence** was presented to **Dr. David Langleben**, from the Division of Cardiology, Department of Medicine, for exceptional care for patients, extensive knowledge of medicine, valued teaching, superior abilities and accessibility to colleagues throughout the

hospital.

Dr Beth Cummings was selected as the 2015 recipient of the Medical Council of Canada W. Dale Dauphinee Fellowship to further her studies in assessment! She will investigate how, why and when benefits of longitudinal integrated curricula are threatened by misalignment between assessment practices and desired curricular outcomes.

Residents' Awards

Dr. Jessica Thom was the recipient of the Dr. Harold Frank Prize for her presentation entitled "The Case of the Dropping EF" at the Clinical Vignettes Evening of the McGill Department of Medicine.

Dr. Paraish Misra received the Dave Feder award. This award is presented to the resident who practices medicine with most compassion and sensitivity, displays kindness, respect and camaraderie towards colleagues and educators and carries a positive outlook enabling him/her to enjoy a meaningful balanced life beyond his/her profession.

Dr. Andrew Weinstock received the Dr. Allen Spanier Internal Medicine Award. This award is given to the resident who exhibits an enduring passion for the practice of medicine, through the enjoyment of solving challenges of patient care and sharing solutions with others, while maintaining a high level of professionalism.

Dr. Julia Chabot was the recipient of the Sheldon Zemelman Memorial Award given to for academic excellence and outstanding contribution to patient care.

Dr. Alastair Dorreen was the recipient of the Medical Resident Research Award. This award is given to the medical resident who has achieved excellence with regard to intellectual curiosity, initiative, originality and accomplishment in medical research performed during residency.

Dr. Jed Lipes was voted as Teacher of the Year by the residents.

VI. Research

The Department of Medicine research activities have been supported by both external funding agencies and by its own Clinical Research Awards, to which are now added the endowment funds and the **Academic Excellence Award of the Auxiliary**.

Dr. Laeora Berkson received in 2015 JGH Auxiliary - Department of Medicine Academic Enrichment Award. The award included \$2,500, the proceeds of an endowment provided by the Auxiliary to mark the 2008 Doctors' Gala.

Research Funding

Total funding from external peer review granting agencies to JGH researchers in 2015-2016 was \$39,075,596 (Medicine 29,983,698). During the period from July 2015 to June 2016, nine (9) clinician-scientists are holding prestigious career awards, fellowship awards or research chairs from various granting agencies, totaling \$625,354.

Department of Medicine Clinical Research Award

The goal of this award is to contribute to the academic development of the Department, and to encourage full-time GFT-H members involved in clinical research by compensating, in part, their time dedicated to clinical research activities. In April 2015, the Research Advisory Committee reviewed applications based on quality of projects, role and productivity of applicant, likelihood of publication in a peer-reviewed scientific journal and awarded three (3) new applicants, renewed twelve (12) previous applicants (5 renewals and 7 extra year grant). The support has increased from an original budget of \$30,000 in 2007 to \$188,000 in 2015.

Publications

The number of publications authored by members of the Department of Medicine was 357 in 2015.

VII. Departmental Activities

The Department continues to reinforce democratic and transparent management in all areas.

VIII. MUHC and McGill

Our relationship with the MUHC has been characterized by collaboration and collegiality. Our commitment to excellence in teaching at both the undergraduate and postgraduate level continues to be valued by McGill University

Within the hospital progress has been made. The Division of Gastroenterology moved into new facilities during the renovations. The Department continues to work towards maintaining its academic mission with improved staffing and resource allocation.

The Department gratefully recognizes the support of the Hospital Administration in its recruitment efforts.

1.2 OBJECTIVES AND PRIORITIES

The Department of Medicine continues to play a key national and international role with many members active across Canada and in the international academic arena, including Dr. Ernesto L. Schiffrin as President of Hypertension Canada and Immediate Past President of the International Society of Hypertension. As well, Dr. Schiffrin became the Editor-in-Chief of the American Journal of Hypertension starting January 2016, although effectively since the last days of December 2015.

We remain dedicated to ensure that the department continues to provide the excellent care to the patients of the hospital for which it is renowned, while at the same time maintaining its goals of excellence in teaching. The recruitment of highly qualified and competitive physician scientists has reinforced the research capacity of the department and has had a transformative effect on the ability of the hospital to serve as a translational science center. It has been challenging to provide conditions that are competitive with the best North American centers due to constraints in funding for personal support, operating monies and up-to-date equipment, as well as difficulties in ensuring adequate space allocation and support services. Despite these difficulties and constraints, we have been successful as can be seen above in already recruiting a considerable group of young physician-educators and physician-scientists in the areas of internal medicine, cardiology, endocrinology, hematology, pulmonary medicine, rheumatology and nephrology, all of who have a good chance of success in scientific competition for the scarce resources currently available locally, provincially and nationally. We have put in place a program that will also help support the research by contract academic staff (CAS, previously called GFT-H) physicians.

Respectfully submitted,

Ernesto L. Schiffrin, C.M., MD, PhD, FRSC, FRCPC, FACP
Physician-in-Chief

2. GRAND MEDICAL ROUNDS & INVITED SPEAKERS (January 1 - December 31, 2015)

January 12	Reassurance for Both Patients and Treating Specialists with Novel Oral Anticoagulants: What Long Term Data Are Confirming	Christian Constance, MD, CHUM
January 19	Ebola Virus Disease: What Have We Learned? Where Are We Going?	Allison McGeer MD, University of Toronto
January 26	Transcatheter Aortic Valve Replacement in 2015: Knowing When to Restore Flow and When to Turn off the Tap	Guiseppa Martucci, MD, MUHC & Jonathan Afilalo, MD, JGH
February 2	19th Annual Humanization of Care Awareness Program: I. Civility and Respect - the Foundation for Good Mental Health at Work II. A Wider Understanding of Healing	Frema Engel, MSW, TS Consultant, Facilitator, Trainer Rabbi Michael Whitman, Hampstead
February 9	I. A Young Woman with Castleman's Disease II. Thrombotic Microangiopathies - a Focus on TTP and TTP-like syndromes	Andrew Weinstock, MD & Daniel Blum, MD Int. Med. 3rd Year Residents, McGill-JGH
February 16	New Insights into the Management of Venous Thromboembolism in Patients with Cancer	Vicky Tagalakis, MD, JGH
February 23	The New Dynamic in US Health Care	Shalom Jacobovitz, CEO, American College of Cardiology
March 2	Order Sets - an Effective Approach to Improving Quality and Health Care Team Efficiency	Chris O'Connor, MD, Critical Care Physician Trillium Health Partners, Think Research
March 9	Clinical Ethics Rounds: Voluntary Euthanasia and Physician Assisted Suicide: What Do You Need to Know?	Lucie Wade, MSc, MUHC
March 16	Ashkenazi Jewish Screening at the MUHC and the JGH: Where Are We At? Where Are We Going?	Charity Fan, Guillaume Sillon, McGill University & Julie Kristof, JGH
March 23	Management of the Hypopit Patient Post Pituitary Surgery	Peter Assimakopoulos MD, JGH
March 30	Perioperative Management of Patients on Warfarin or Novel Oral Anticoagulants: a Practical, Case-based Approach	James Douketis, MD, McMaster University
April 13	Drugs and Geriatric Syndromes	Joseph T. Hanlon, Pharm D, MS, University of Pittsburg
April 20	Acute Kidney Injury in the ICU: New Definitions, Same Old Controversies	Ron Wald, MD, St. Michael's Hospital, Toronto
April 27	Macrophage Activation Syndrome in Internal Medicine	Alexei Grom, MD, University of Cincinnati
May 4	I. From Experiment to Cure: a Success Story in the Treatment of Low Malignant Potential Tumors of the Ovary II. The Use of Point of Care Ultrasound in the Management of Heart Failure	Kashayar Esfahani, MD, 3rd Year Internal Medicine Resident, McGill-JGH Rachel Spevack, MD, 2nd Year Internal Medicine Resident, McGill-JGH
May 11	Minimally Invasive Lung Cancer Staging and Treatment. Past, Present and Future	Moishe Liberman, MD, PhD, CHUM
May 25	Paraneoplastic Neurologic Syndromes	Robert Altman, MD, JGH
June 8	Lessons Learned from Reading the Genetic Code of Acute Myeloid Leukemia: Where Do We Go Next?	François Mercier, MD, McGill University
June 15	Neuroendocrine Tumor of the GI Tract: Improving Outcomes Through Better Understanding	Petr Kavan, MD, PhD, JGH
September 8	Tuesday Special Medical Grand Rounds: Recent Advance in Cardiovascular Outcomes Trials with Antihyperglycemic Agents	Faiez Zannad, MD, PhD, University of Nancy, France
September 21	27th Annual Bertha & Nachum Mizne Memorial Lecture: GI Cancer Risk in Non-GI Hereditary Cancer Syndromes	Polymnia Galiatsatos, MD, JGH
September 28	First Annual Department of Medicine Clinical Research Symposium: I. Integrating 3-D, Strain Imaging and Biomarkers for the Prevention of Chemotherapy-Induced Cardiotoxicity II. Targeted Destruction of Tagged Cells As A Goal in Cancer Management III. Understanding the Genetic Complexity of Diffuse Large B Cell Lymphoma in the Context of A Clinical Trial for Relapsed Disease	Igal Sebag, MD, JGH Michael Tamilia, MD, JGH Sarit Assouline, MD, JGH
October 5	Allergy Update 2015: I. New Therapy for Allergic Rhinitis II. New Diagnostics in Allergy	Peter Small, MD, JGH
October 19	New Diagnostic and Therapeutic Approaches To Mycosis Fungoides and Sezary Syndrome	Alain H. Rook, MD, University of Pennsylvania, Philadelphia, PA & Youn H. Kim, MD, Stanford University Medical Center, Stanford, CA
October 26	Canadian Patient Safety Week: I. Walking the Talk with Evidence Based Medicine: Assessing the Quality of Medical Practice II. Nephrology & Neurology: the Benchmarking of Clinical Outcomes	Nicolas Bustamante, MD, 1st Yr Fam Med Resident, McGill - JGH Emad Tawfik, MHA & Mendy Sananikone-Thavonekham, BSc, MHA, University of Montreal
November 2	Less Medicine More Health: 7 Assumptions That Drive Too Much Medical Care	H. Gilbert Welch, MD, MHP, Dartmouth Institute for Health Policy & Clinical Research
November 9	Solving Immune Thrombocytopenia (ITP)	Donald M. Arnold, MD, McMaster University
November 16	Evolving Role of Robotics in Cardiac Surgery - Do the Ends Justify the Cost?	Emmanuel Moss, MD, MSc, JGH
November 23	A Modern Approach in the Management of IBS and CIC (Chronic Idiopathic Constipation)	Paul Moayyedi, MB ChB, PhD (Leeds), McMaster University
November 30	The McGill Internal Medicine Global Health Initiative: Haiti 2015	Rachel Spevack, MD, 3rd Yr Int. Med. Resident, McGill University & JGH Laura Anne Habib, MD, Int. Med. Resident, PGY2, McGill University & MUHC
December 7	Early Ambulation in the ICU	Paul Warshawsky, MD, FRCPC, JGH
December 14	An Update on Acute Stroke Management	Jeffrey Minuk, MSc, MD, FRCPC, JGH

3. UNDERGRADUATE AND POSTGRADUATE TEACHING REPORTS

A. REPORT OF UNDERGRADUATE TEACHING - DECEMBER 2015

There continues to be exciting progress in the undergraduate education program.

Clerkship Structure

- New 16-week system
 - Alternating between surgery and internal medicine
- New pass-fail system
- New outpatient oncology clinic
- New academic half-day
 - JGH Attending did their share, thus no more lectures this year for clerkship.
- New evaluation system
 - New forms for CCU, CTU and ERC
 - P-mex form (to evaluate none medical expert items in specific settings)
- Evaluation forms must be filled in within 2 weeks of the end of the Attending's time with the students.
- Feedback
 - q2 weeks on 7W & 7NW, q week for CCU & ERC

Clerkship Workload Policy

- Workload policy (may be changing...)
 - No more than 60 hours/week (excluding calls)
 - No more than 85 hours/week (including calls)
 - No more than 12 hours/day when not on call
 - No more than 16 hours/day when on call
 - Weekend includes Monday STAT days
 - 7 days off (5 weekdays & 2 weekends) for Christmas or New Year

Weekly tracking of the hours by our office, but despite this, we had 7 flags for weeks exceeding 85-hours.

Review, Assess, Consolidate (RAC) and Transition to clinical practice (TCP)

RAC

- Starting today, over 2 week
- JGH always the easiest site when it comes to recruit Attendings to teach
- New remuneration system
- For this year, it will be paid by the Faculty

TCP

- From January 4 – June 19, 2016
- Participation from all divisions
- 6 weeks of Internal Medicine and 2 weeks of Neurology
- Academic half-day (Thursday am) and Physician expert round (8:00-9:30) and EKG teaching.
- For this year, it will be paid by the Faculty

Dr. Saad expressed her appreciation for the participation and dedication from all Divisions of Medicine to UGME teaching.

Respectfully submitted,

Nathalie Saad, MD
Director, Undergraduate Education

B. POSTGRADUATE TEACHING REPORT - DECEMBER 2015

CaRMS 2016:

The JGH has done exceptionally well in CaRMS again this year, with all JGH core internal medicine PGY3's having placed in their first choice specialty. The PGY1 match results will be released in early March and we look forward to meeting the new recruits.

Program Changes

CTU:

The clinical teaching units that were previously on 7 west and 7 northwest have moved to the beautiful new pavilion and are now on K6 and K7 respectively. The composition of the medical teams on each ward has not changed. We are presently in the midst of outfitting the conference rooms on each floor with state of the art technology with the goal of optimizing the educational environments there. This project has been made possible thank to generous funding from McGill, the JGH, and the JGH foundation.

Teaching Rounds:

CTU lunch rounds were formally introduced 9 months ago and will continue, as they have been a resounding success. With lunch provided by the department, these teaching sessions take place on either the Tuesday or Wednesday of weeks 2 and 3 of each period. Fellows from a mix of specialties have pitched in to give talks and run through informal Royal College-style scenarios that have received great feedback from residents of all years of training.

Morning report will continue for the first 3 Fridays of each period, from 7:45 am to 8:30 am.

Radiology rounds will continue every second and fourth Tuesday from 8 am to 9 am.

CVICU/CVU:

The former acute cardiology unit has joined with the former cardiac surgery unit under the cardiovascular in-patient unit. Residents will continue to staff the new unit in the same numbers as they had previously.

Outpatient experience:

The JGH Resident Academic Committee recently composed a position paper detailing the perceived lack of outpatient exposure during core internal medicine residency, and solutions that would improve training in the out-patient setting. In a survey, 94% of recent graduates from the JGH internal medicine residency program felt that their outpatient clinical experience was insufficient and 88% felt that a greater outpatient clinic experience would help them better prepare for their eventual career. In particular, these graduates felt they would have benefited tremendously from greater ambulatory medicine exposure in endocrinology and metabolism, rheumatology, gastroenterology, general internal medicine and nephrology. One recommendation suggested in this position paper is to restructure electives such that at least one quarter of any rotation in a subspecialty is in an outpatient setting. This can be accomplished by implementing a 3:1 structure, where 3 weeks are dedicated to inpatient consults and 1 week is dedicated to clinics. This structure can minimize the tension arising from managing responsibilities in multiple clinical arenas simultaneously. We hope to work with elective supervisors to implement these recommended changes in the coming months, in response to these important concerns coming from our recent trainees.

Resident Research:

The resident research afternoon will be May 25, 2016, and PGY3's from all 3 base hospitals will

again be preparing poster presentations on their research.

Local Simulation:

With many thanks to Dr. Errol Stern, we have recommenced internal medicine simulations with the high-fidelity model in pavilion A. A curriculum of simulation scenarios has been designed by internal medicine senior residents based on real experiences they have had with deteriorating patients. During 1-2 academic half days per month, a handful of junior and second year residents run simulations with the scenario-builder and Dr. Stern as facilitators in pavilion A. To date the feedback has been excellent, and we hope to continue this exciting project in the years to come.

McGill Simulation Centre:

It remains difficult to recruit staff for the McGill Simulation Centre sessions resulting in some sessions being cancelled due to staff shortages.

Holiday Party:

We would like to thank you for the excellent turnout for the Holiday Party which was held December 14 at Porto Vino.

We want to again thank all the JGH staff for their enthusiasm, dedication, and ongoing commitment to teaching.

Respectfully submitted,

Rubin Becker, MD
Interim Program Director, JGH Postgraduate Medical Education

GENERAL INTERNAL MEDICINE HOUSESTAFF LIST JULY 1, 2015 - JUNE 30, 2016

CHIEF RESIDENTS

Blum, Daniel (July 1 - December 31, 2015)

Awan, Asif (January 1 - June 30, 2016)

R3

Ait Mohamed, Imene

Aloe, Stephanie

Asundi, Archana

Awan, Asif

Blum, Daniel

Dubrofsky, Lisa

Elbaz, Carolyne

Esmaiel, Abdullah

Heron, Valerie

Roudaia, Liya (Periods 1-4 Only)

Savard, Marie-France

Spevack, Rachel

Buhlaiga, Najwa (Periods 1-4)

Alahdal, Duaa (Periods 4-13)

R2

Almhri, Ali

Cafaro, Teresa

Feteih, Abeer

Hnaris, Konstantinos (Kosta)

Huertas Garcia, Julian

Miller, Corey

Myran, Daniel

Pancer, Jill

Paquin, Amelie

Srinivasan Sridhar, Vikas

Strohl, Matthew

Tran, Anh Tram (Stephanie)

Zhao, Nan

Alahdal, Duaa Medical Biochemistry

R1

Beliavsky, Alina

D'aoust, Julie

Hyppolite, Jessie Jean

Jha, Mayank Monal

Korsos, Victoria

Li, Shen

Liu, Xing Jian

Nathoo, Natasha

Nguyen, Thi Kim Hanh

Fallah, Parvanah (Starts Period 13-2015)

Raslan, Ismail

Radi, Suhaib

Swaleh, Sana

Schweitzer, Lorne

OTHER PROGRAMS

Shamout, Yassein Dermatology (1-12)

Banon, Olivier Dx Radiology (1-6)

Toupin, Jean-Francois Dx Radiology (1-6)

Attarian, Armen Dx Radiology (7-11)

Tsui, James Radiation Oncology (1-13)

Nassralla H, Georges Ophthalmology (1-11)

Shalabi, Nabeel Ophthalmology (1-11)

Parks, Andrea Neurology (1-13)

Adbulfata H, Alayoubi Medical Genetics (1-5)

4. EXTERNAL RESEARCH GRANTS & AWARDS

A. Career Awards - July 2015 - June 2016 (Clinician-Scientists)

Name	Agency	Expiry Date	Amount
AFILALO, Dr. J.	Heart & Stroke	30-Jun-2016	31,486
ASSOULINE, SARIT.	FRQS	30-Jun-2018	37,538
HUDSON, Dr. M.	FRQS	30-Jun-2015	38,227
JOHNSON, Dr. N.	FRQS	30-Jun-2016	83,333
KAHN, Dr. S.	Canada Research Chair	20-Sept-2021	120,000
LONGTIN, Dr. Y.	FRQS	30-Jun-2017	39,377
RICHARDS, B.	FRQS	30-Jun-2019	35,393
	Jody Ginsberg Young Inv.	30-June -2015	20,000
	William Dawson	30-June-2020	15,000
SCHIFFRIN, Dr. E.	Canada Research Chair	31-Dec-2019	145,000
VEDEL, Dr. I.	CIHR	30-Jun-2019	60,000
TOTAL:			625,354

B. Grants & Bursaries 2015-2016

See attached Excel File

5. NEW HONORS, AWARDS AND APPOINTMENTS (SEE APPENDIX A)

6. PUBLICATIONS (January - December 2015)

Afilalo, Jonathan

--Mamane S, Mullie L, Piazza N, Martucci G, Morais J, Vigano A, Levental M, Nelson K, Lange R, **Afilalo J**. Psoas Muscle Area and All-Cause Mortality After Transcatheter Aortic Valve Replacement: The Montreal-Munich Study. *Can J Cardiol*. 2016 Feb;32(2):177-82. doi: 10.1016/j.cjca.2015.12.002. Epub 2015 Dec 9. PubMed PMID: 26821840.

--Senaratne JM, Norris CM, Graham MM, Galbraith D, Nagendran J, Freed DH, **Afilalo J**, Van Diepen S; APPROACH Investigators. Clinical and angiographic outcomes associated with surgical revascularization of angiographically borderline 50-69% coronary artery stenoses†. *Eur J Cardiothorac Surg*. 2016 Jan 29. pii: ezw005. [Epub ahead of print] PubMed PMID: 26825107.

--Claveau D, Piha-Gossack A, Friedland SN, **Afilalo J**, Rudski L. Complications Associated With Nitrate Use in Patients Presenting With Acute Pulmonary Edema and Concomitant Moderate or Severe Aortic Stenosis. *Ann Emerg Med*. 2015 Oct;66(4):355-362.e1. doi: 10.1016/j.annemergmed.2015.03.027. Epub 2015 May 19. PubMed PMID: 26002298.

--Goldfarb M, Drudi L, Almohammadi M, Langlois Y, Noiseux N, Perrault L, Piazza N, **Afilalo J**. Outcome Reporting in Cardiac Surgery Trials: Systematic Review and Critical Appraisal. *J Am Heart Assoc*. 2015 Aug 17;4(8):e002204. doi: 10.1161/JAHA.115.002204. PubMed PMID: 26282561; PubMed Central PMCID: PMC4599473.

--**Afilalo J**, Grapsa J, Nihoyannopoulos P, Beaudoin J, Gibbs JS, Channick RN, Langleben D, Rudski LG, Hua L, Handschumacher MD, Picard MH, Levine RA. Leaflet area as a determinant of tricuspid regurgitation severity in patients with pulmonary hypertension. *Circ Cardiovasc Imaging*. 2015 May;8(5). pii: e002714. doi: 10.1161/CIRCIMAGING.114.002714. PubMed PMID: 25977303; PubMed Central PMCID: PMC4435735.

--Stammers AN, Kehler DS, **Afilalo J**, Avery LJ, Bagshaw SM, Grocott HP, Légaré JF, Logsetty S, Metge C, Nguyen T, Rockwood K, Sareen J, Sawatzky JA, Tangri N, Giacomantonio N, Hassan A, Duhamel TA, Arora RC. Protocol for the PREHAB study-Pre-operative Rehabilitation for reduction of Hospitalization After coronary Bypass and valvular surgery: a randomised controlled trial. *BMJ Open*. 2015 Mar 9;5(3):e007250. doi: 10.1136/bmjopen-2014-007250. PubMed PMID: 25753362; PubMed Central PMCID: PMC4360727.

--Lang RM, Badano LP, Mor-Avi V, **Afilalo J**, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015 Mar;16(3):233-70. doi: 10.1093/ehjci/jev014. Review. PubMed PMID: 25712077.

--Lang RM, Badano LP, Mor-Avi V, **Afilalo J**, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015 Jan;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003. PubMed PMID: 25559473.

Alaoui-Jamali, Moulay

--da Silva SD, Marchi FA, Xu B, Bijian K, Alobaid F, Mlynarek A, Rogatto SR, Hier M, Kowalski LP, and **Alaoui-Jamali MA**. Genome-wide analysis of Rab GTPases in metastatic oral squamous cell carcinoma. *Oncotarget*. 2015 Sep 8;6(26):21950-63.

--**Alaoui-Jamali MA**, Morand GB, da Silva SD. ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics. *Front Genet*. 2015 Feb 4;6:17, 1-9.

--Peña-Hernández R, Marques M, Hilmi K, Zhao T, Saad A, **Alaoui-Jamali MA**, Del Rincon SV, Ashworth T, Roy AL, Emerson BM, Witcher M. Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I. *Proc Natl Acad Sci U S A*. 2015 Feb 17;112(7):E677-86.

--da Silva SD, Morand GB, Alobaid FA, Hier MP, Mlynarek AM, **Alaoui-Jamali MA**, Kowalski LP. Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma. *Clin Exp Metastasis*. 2015 Jan;32(1):55-63.

Assayag, Deborah

--**Assayag D**, Ryerson CJ. Determining Respiratory Impairment in Connective Tissue Disease– Associated Interstitial Lung Disease. *Rheumatic Disease Clinics*.41(2):213-223.

--**Assayag D**, Kim EJ, Elicker BM, et al. Survival in interstitial pneumonia with features of autoimmune disease: A comparison of proposed criteria. *Respir. Med.*;109(10):1326-1331.

--**Assayag D**, Vittinghoff E, Ryerson CJ, et al. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. *Respir. Med.*;109(8):1058-1062.

Assouline, Sarit

--Morin RD, **Assouline SE**, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Holm Nielsen T, Petrogiannis-Halioitis T, Crump M, Tosikyan A, Grande BM, Macdonald D, Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y, Klein-Oros K, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E, Constantin AM, Pan-Hammarström Q, Peng RJ, Mann KK, **Johnson NA**. Geneticlandscapes of relapsed and refractory diffuse large B cell lymphomas. *Clin Cancer Res*. 2015 Dec 8. [Epubahead of print]

--Andreeff M, Kelly KR, Yee K, **Assouline S**, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.*Clin Cancer Res*. 2015 Oct 12. [Epubahead of print]

--Owen C, **Assouline S**, Kuruvilla J, Uchida C, Bellingham C, Sehn L. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective. *Clin Lymphoma Myeloma Leuk*. 2015 Nov;15(11):627-634.

--Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, **Assouline S**, D'Emilio A, Gozzini A, Giraldo P, Stagno F, Iurlo A, Luciani M, De Riso G, Redaelli S, Kim DW, Pirola A, Mezzatesta C, Petroccione A, Lodolo D'Oría A, Crivori P, Piazza R, Gambacorti-Passerini C. Age and dPCR can predict relapse in CML patients who discontinue imatinib: the ISAV study. *Am J Hematol*. 2015 Oct;90(10):910-4.

--Palanca-Wessels MC, Czuczman M, Salles G, **Assouline S**, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.*Lancet Oncol*. 2015 Jun;16(6):704-15.

--**Assouline S**, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, Catalani O, Hourcade-Potelleret F, Sayyed P, Badoux X. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. *Br J Clin Pharmacol*. 2015 Nov;80(5):1001-9.

--Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, Ghosn M, Mehta A, Packman S, Pastores G, Petakov M, **Assouline S**, Balwani M, Danda S, Hadjiev E, Ortega A, Shankar S, Solano MH, Ross L, Angell J, Peterschmitt MJ. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. *JAMA*. 2015 Feb 17;313(7):695-706.

--Marton A, Kezouh A, Petrogiannis-Halioitis T, **Assouline S**. Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials. *Leuk Lymphoma*. 2015 Sep;56(9):2747-9.

--**Assouline S**, Culjkovic-Kraljacic B, Bergeron J, **Caplan S**, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH Jr., Borden KLB. A Phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. *Haematologica*,100 (1) e7-e9, DOI: 10.3324/haematol.2014.111245, 2015.

Autexier, Chantal

--Chu TW, D'Souza Y and **Autexier C**. 2015. The Insertion in Fingers Domain in human telomerase can mediate enzyme processivity and telomerase recruitment to telomeres in a TPP1-dependent manner. *Molecular and Cellular Biology*, 36, 210-222

--Mancini J, Rousseau P, Castor, KJ, Sleiman H. and **Autexier C**. 2016. Platinum (II) Phenanthroimidazole G-Quadruplex Ligand Induces Selective Telomere Shortening in A549 cancer cells. *Biochimie*, 121,287-297. Epub 2015 Dec 25

--Rousseau P and **Autexier C**. 2015. Telomere biology: Rationale for diagnostics and therapeutics in cancer. *RNA Biology*, 12, 1078-1082.

--Spinella JF, Cassart P, Garnier N, Rousseau P, Drullion C, Richer C, Ouimet M, Vidal R, Saillour V, Healy J, **Autexier C**. and Daniel Sinnett. 2015. A rare somatic mutation in TPP1 induces telomere lengthening and apoptosis resistance in leukemia cells. *BMC Cancer*, 15, 621-628.

Baron, Murray

--**Baron M**, Pope JE, F VDH, Khanna D, Fransen J, Johnson SR, Matucci-Cerinic M. Specificity of Systemic Sclerosis Classification Criteria. *The Journal of rheumatology* 2015;42:2512.

--Dagenais M, MacDonald D, **Baron M**, Hudson M, Tatibouet S, Steele R, Gravel S, Mohit S, El Sayegh T, Pope J, Fontaine A, Masetto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Gornitsky M. The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. *Oral surgery, oral medicine, oral pathology and oral radiology* 2015;120:104-11.

--**Baron M**, Hudson M, Tatibouet S, Steele R, Lo E, Gravel S, Gyger G, El Sayegh T, Pope J, Fontaine A, Masetto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira G, Robinson D, Fritzler M, Gornitsky M. Relationship between disease characteristics and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III. *Arthritis care & research* 2015;67:681-90.

--**Baron M**, Hudson M, Tatibouet S, Steele R, Lo E, Gravel S, Gyger G, El Sayegh T, Pope J, Fontaine A, Masetto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Gornitsky M. The Canadian systemic sclerosis oral health study II: the relationship between oral and global health-related quality of life in systemic sclerosis. *Rheumatology (Oxford, England)* 2015;54:692-6.

--Kwakkenbos L, Minton O, Stone PC, Alexander S, **Baron M**, Hudson M, Thombs BD. Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. *The Journal of rheumatology* 2015;42:1156-62.

--Morardet L, Avouac J, Sammour M, **Baron M**, Kahan A, Feydy A, Allanore Y. Late nailfold videocapillaroscopy patterns associated with hand calcinosis and acro-osteolysis in systemic sclerosis. *Arthritis care & research* 2015.

Batist, Gerald

--Rodon J, Soria JC, Berger R, **Batist G**, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH Jr, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in Initiating and Conducting Personalized Cancer Therapy Trials: Perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium Trial. *Annals of Oncol* 26(8):1791-8, 2015.

Beauchet, Olivier

--Annweiler C, Denis S, Duval G, Ferland G, Bartha R, Beauchet O. Use of Vitamin K Antagonists and Brain Volumetry in Older Adults: Preliminary Results From the GAIT Study. *J Am Geriatr Soc*. 2015 Oct;63(10):2199-202.

--Allali G, Annweiler C, Blumen HM, Callisaya ML, De Cock AM, Kressig RW, Srikanth V, Steinmetz JP, Verghese J, **Beauchet O**. Gait phenotype from mild cognitive impairment to moderate dementia: results from the GOOD initiative. *Eur J Neurol*. 2015 Dec 14. doi: 10.1111/ene.12882. [Epub ahead of print]

--Allali G, Annweiler C, Predovan D, Bherer L, **Beauchet O**. Brain volume changes in gait control in patients with mild cognitive impairment compared to cognitively healthy individuals; GAIT study results. *Exp Gerontol*. 2015 Dec 16. pii: S0531-5565(15)30106-6. doi: 10.1016/j.exger.2015.12.007. [Epub ahead of print]

Bergman, Howard

--Rodriguez C, Bartlett-Esquilant G, Boillat M, Dove M, Grad R, Lalla L, Pluye P, Tellier P-P, **Bergman H**. Manifesto for family medicine educational research. *Canadian Family Physician*. 2015 Sep;61(9):745-7.

Blank, Volker

--Gasiorek JJ, Mikhael M, Garcia-Santos D, Hui ST, Ponka P & **Blank V**. Thioredoxin-interacting protein regulates the differentiation of murine erythroid precursors. *Experimental Hematology* 43: 393-403, 2015.

--Gasiorek JJ & **Blank V**. Regulation and function of the NFE2 transcription factor in hematopoietic and non-hematopoietic cells. *Cellular & Molecular Life Sciences* 72: 2323-35, 2015.

--Kannan MB, Dodard-Friedman I & **Blank V**. Stringent control of NFE2L3 (Nuclear Factor, Erythroid 2-Like 3; NRF3) protein degradation by FBW7 (F-box/WD Repeat-containing Protein 7) and glycogen synthase kinase 3 (GSK3). *Journal of Biological Chemistry* 290: 26292-302, 2015.

Blostein, Mark

--Bertin FR, Lemarié CA, Robins RS, **Blostein MD**. Gas6 regulates thrombin-induced expression of VCAM-1 through FoxO-1 in endothelial cells. *J Thromb Haemost*. 2015 Sep 28. [Epub ahead of print]

--Ibrahim, R., B. Kucukyazici, V. Verter, M. Gendreau, **M. Blostein**, "Designing Personalized Treatment: An Application to Anticoagulation Therapy", forthcoming in *Production and Operations Management*, (accepted September 2015)

--Marc Carrier, MD, Alejandro Lazo-Langner, MD, Sudeep Shivakumar, MD, Vicky Tagalakakis, MD, Ryan Zarychanski, MD, Susan Solymoss, MD, Nathalie Routhier, MD, James Douketis, MD, Kim Danovitch, CCRP, Agnes Y. Lee, MD, Gregoire Le Gal, MD, Philip S. Wells, MD, Daniel J. Corsi, PhD, Timothy Ramsay, PhD, Doug Coyle, PhD, Isabelle Chagnon, MD, Zahra Kassam, MD, Hardy Tao, MD, and Marc A. Rodger, MD, for the SOME Investigators*. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. *N Engl J Med.* 2015 Aug 20;373(8):697-704. * **M Blostein** Local site investigator

--Charles V. Pollack, Jr., MD, Paul A. Reilly, PhD, John Eikelboom, MB, BS, Stephan Glund, PhD, Peter Verhamme, MD, Richard A. Bernstein, MD, PhD, Robert Dubiel, PharmD, Menno V. Huisman, MD, PhD, Elaine M. Hylek, MD, Pieter W. Kamphuisen, MD, PhD, Jörg Kreuzer, MD, Jerrold H. Levy, MD, Frank W. Sellke, MD, Joachim Stangier, PhD, Thorsten Steiner, MD, M.M.E., Bushi Wang, PhD, Chak-Wah Kam, MD, and Jeffrey I. Weitz, MD* Idarucizumab for Dabigatran Reversal. *N Engl J Med.* 2015 Aug 6; 373:511-520 . * **M Blostein** Local site investigator

--Schulman S, Carrier M, Lee AY, Shivakumar S, **Blostein MD**, Spencer FA, Solymoss S, Barty R, Wang G, Heddle N, Douketis JD. Perioperative Management of Dabigatran: A Prospective Cohort Study. *Circulation.* 2015 Jul 21;132(3):167-73.

--James D. Douketis, MD, Alex C. Spyropoulos, MD, Scott Kaatz, D.O., Richard C. Becker, MD, Joseph A. Caprini, MD, Andrew S. Dunn, MD, David A. Garcia, MD, Alan Jacobson, MD, Amir K. Jaffer, MD, MBA, David F. Kong, MD, Sam Schulman, MD, PhD, Alexander G.G. Turpie, MB, Vic Hasselblad, PhD, and Thomas L. Ortel, MD, PhD for the BRIDGE Investigators.* Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. *N Engl J Med,* 2015; 373:823-833. * **M Blostein** Local site investigator

Chalifour, Lorraine

Bhavini B. Patel, Mohammad Raad, **Igal A Sebag** and Lorraine **E. Chalifour.** (2015). Sex-specific cardiovascular responses to control or high fat diet feeding in C57bl/6 mice chronically exposed to bisphenol A. *Toxicology Reports* 2: 1310-1318.

Bhavini B. Patel, Amanda Kasneci, Alicia M. Bolt Vanessa Di Lalla, Massimo R. Di Iorio, Mohamad Raad, Koren **K. Mann** and **Lorraine E Chalifour.** (2015). Chronic exposure to bisphenol A reduces successful cardiac remodeling after an experimental myocardial infarction in C57bl/6n mice. *Toxicological Sciences.* 146(1): 101-115.

Chen-Tournoux, Annabel

--Tan TC, Flynn AW, **Chen-Tournoux A**, Rudski LG, Mehrotra P, Nunes MC, Rincon LM, Shahian DM, Picard MH, Afilalo J. Risk Prediction in Aortic Valve Replacement: Incremental Value of the Preoperative Echocardiogram. *J Am Heart Assoc.* 2015 Oct 26;4(10):e002129. doi: 10.1161/JAHA.115.002129. PubMed PMID: 26504147.

Chertkow, Howard

--Kertesz A, Finger E, Murrell J, **Chertkow H**, Ang Lee C, Baker M.C, Ravenscroft T, Rademakers, & R. Munoz DG (2015). Progressive Supranuclear Palsy in a family with TDP-43 pathology. *Neurocase.* doi: 10.1080/13554794.2013.878729. PMID: 24479957. 21(2): 178-84.

--Cloutier S, **Chertkow H**, Kergoat M-J, Gauthier S, & Belleville S (2015). Patterns of cognitive decline prior to dementia in persons with mild cognitive impairment. *Journal of Alzheimer's Disease,* doi: 10.1088/0031-9155/60/20/8161. 47(4): 901-13.

--Zirnheld AL, Regalado EL, Shetty V, **Chertkow H**, Schipper HM, & Wang E. Target genes of circulating miR-34c as plasma protein biomarkers of Alzheimer's disease and mild cognitive impairment. *Journal of Aging Science*; 3:2, 2015 <http://dx.doi.org/10.4172/2329-8847.1000140>

--Tam A, Dansereau C, Badhwar A, Orban P, Belleville S, **Chertkow H**, Dagher A, Hanganu A, Monchi O, Rosa-Neto P, Shmuel A, Wang S, Breitner J, & Bellec P (2015). Common effects of amnesic mild cognitive impairment on resting-state connectivity across four independent studies. *Frontiers in Aging Neuroscience*, doi: 10.3389/fnagi.2015.00242.

Cohen, Robin

--*Allen D, Badro V, Denyer Willis L, Macdonald ME, Paré A, Hutchinson T, Barré P, Beauchemin R, Bocti H, Broadbent A, **Cohen SR**. Fragmented care and whole-person illness: Decision-making for people with chronic, end-stage kidney disease. *Chronic Illness* 2015; 11(1):44-55. doi: 10.1177/1742395314562974

--Lang A, Toon L, **Cohen SR**, Stajduhar K, Griffin M, Easty T, Williams A. Client, caregiver, and provider perspectives of safety issues in palliative home care: A mixed method design. *Safety in Health* 2015; 1:3. doi: 10.1186/2056-5917-1-3

--*MacKinnon CJ, Smith NG, Henry M, Milman E, Chochinov HM, Körner A, Berish M, Farrace A, Liarikos N, **Cohen SR**. Reconstructing meaning with others in loss: A feasibility pilot randomized controlled trial of a bereavement group. *Death Studies* 2015; doi:10.1080/07481187.2014.958628

--**Cohen SR** and Sawatzky R. Quality of life assessment in palliative care. In: *Textbook of Palliative Medicine and Supportive Care*, 2nd Edition, E. Bruera, I. Higginson, C.F. von Gunten, and T. Morita eds. CRC Press, London, England. Distributed by Oxford University Press, New York, N.Y.(2015), pp 361-369.

Dascal, Andre

--Kong LY, Dendukuri N, Schiller I, Bourgault AM, Brassard P, Poirier L, Lamothe F, Béliveau C, Michaud S, Turgeon N, Toye B, Frost EH, Gilca R, **Dascal A**, Loo VG. Predictors of asymptomatic *Clostridium difficile* colonization on hospital admission. *Am J Infect Control*. 2015 Mar 1;43(3):248-53. doi: 10.1016/j.ajic.2014.11.024. PMID:25728150

Eisenberg, Mark J.

--Grandi SM, Gervais A, Joseph L, O'Loughlin J, Paradis G, Pilote L, Rinfret S, **Eisenberg MJ**. Assessment of the Validity of Self-Report as a Measure of Smoking Status in Patients Post-Myocardial Infarction. *Can J Gen Intern Med* 2015; 9:137-9.

--Avgil Tsadok M, Jackevicius CA, Essebag V, **Eisenberg MJ**, Rahme E, Pilote L. Warfarin Treatment and Outcomes of Patients With Atrial Fibrillation in Rural and Urban Settings. *J Rural Health* 2015; 31:310-5.

--*Nhan C, Windle SB, **Eisenberg MJ**, *Franck C, Gore G, Budlovsky T, Filion KB. Combination Pharmacotherapies and Behavioral Therapies for Smoking Cessation: A Systematic Review. *Can J Gen Intern Med* 2015; 10:25-36.

--Cooke AB, Toli E, Gomez Y-H, Mutter AF, **Eisenberg MJ**, Daskalopoulou S. From Rest to Stressed: Endothelin-1 Levels in Young Healthy Smokers and Non-Smokers. *Metabolism*. *Metabolism* 2015; 64:1103-11.

--Leung Yinko SSL, Maheswaran J, Pelletier R, Bacon SL, Daskalopoulou SS, Khan NA, **Eisenberg MJ**, Karp I, Lavoie KL, Behloul H, Pilote L, for the GENESIS-PRAXY Investigators. Sex differences in health behavior change after premature acute coronary syndrome. *Am Heart J* 2015; 170:242-248.e3.

--Windle SB, Bata I, Madan M, Abramson BL, **Eisenberg MJ**. A Randomized Controlled Trial of the Efficacy and Safety of Varenicline for Smoking Cessation Following Acute Coronary Syndrome: Design and Methods of the EVITA Trial. *Am Heart J* 2015; 170: 235-241.e1

--Vincent S, Eberg M, **Eisenberg MJ**, Filion KB. A meta-analysis of long-term outcomes of stenting vs endarterectomy for carotid stenosis. *Circ Cardiovasc Qual Outcomes* 2015;8(6 Suppl 3):S99-S108.

--Beauséjour Ladouceur V, Lawler PR, Gurvitz M, Pilote L, **Eisenberg MJ**, Ionescu-Ittu R, Guo L, Marelli AJ. Exposure to Low-Dose Ionizing Radiation From Cardiac Procedures in Patients With Congenital Heart Disease: 15-Year Data From a Population-Based Longitudinal Cohort. *Circulation* 2015; doi: 10.1161/CIRCULATIONAHA.115.019137. [Epub]

--Leung Yinko SS, Pelletier R, Behloul H, Bacon SL, Karp I, Thanassoulis G, Daskalopoulou SS, **Eisenberg MJ**, Khan NA, Lavoie KL, Pilote L; GENESIS-PRAXY investigators. Potential factors associated with fruit and vegetable intake after premature acute coronary syndrome: a prospective cohort study. *Int J Food Sci Nutr* 2015; 66:943-9.

--**Eisenberg MJ**, Windle SB, Roy N, Old W, Grondin F, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR, Baril JF, Lambert CR, Madan M, Abramson B, Dehghani P. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. *Circulation* 2016; 133:21-30.

--Avgil-Tsadok M, Jackevicius CA, Essebag V, **Eisenberg MJ**, Rahme E, Behloul H, Pilote L. Dabigatran Use In Elderly Patients With Atrial Fibrillation. *Thromb Haemost* 2015; 115; 152-60.

--Pelletier R, Khan NA, Cox J, Daskalopoulou SS, **Eisenberg MJ**, Bacon SL, Lavoie KL, Daskupta K, Rabi D, Humphries KH, Norris CM, Thanassoulis G, Behloul H, Pilote L; GENESIS-PRAXY Investigators. Sex Versus Gender-Related Characteristics: Which Predicts Outcome After Acute Coronary Syndrome in the Young? *J Am Coll Cardiol*. 2016; 67:127-35.

Ernst, Pierre

--**Ernst P**, Saad, N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. *Eur Respir J*. 2015 Feb;45(2):525-37. PMID:25537556

--Eilayyan O, Gogovor A, Mayo N, **Ernst P**, Ahmed S. Predictors of perceived asthma control among patients managed in primary care clinics. *Qual Life Res*. 2015 Jan;24(1):55-65 PMID: 24806353

--Brassard P, Vutcovici M, **Ernst P**, Patenaude V, Sewitch M, Suissa S, Bitton A. Increased incidence of inflammatory bowel disease in Québec residents with airway diseases. *Eur Respir J*. 2015 Apr;45(4):962-8. PMID: 25406447

--Peláez S, Lamontagne AJ, Collin J, Gauthier A, Grad RM, Blais L, Lavoie KL, Bacon SL, **Ernst P**, Guay H, McKinney ML, Ducharme FM. Patients' perspective of barriers and facilitators to taking long-term controller medication for asthma: a novel taxonomy. *BMC Pulm Med*. 2015 Apr 25;15(1):42. PMID: 25907709

--Zaihra T, **Ernst P**, Tamblyn R, Ahmed S. Tailoring interventions: identifying predictors of poor asthma control. *Ann Allergy Asthma Immunol*. 2015 Jun;114(6):485-491.e1. PMID: 26021893

--Tamblyn R, **Ernst P**, Winslade N, Huang A, Grad R, Platt RW, Ahmed S, Moraga T, Eguale T. Evaluating the impact of an integrated computer-based decision support with person-centered analytics for the management of asthma in primary care: a randomized controlled trial. *J Am Med Inform Assoc*. 2015 Jul;22(4):773-83. 2015 Feb 10. [Epub ahead of print]. PMID:25670755

--Renoux C, Lix LM, Patenaude V, Bresee LC, Paterson JM, Lafrance JP, Tamim H, Mahmud SM, Alsabbagh MW, Hemmelgarn B, Dormuth CR, **Ernst P**; Canadian Network of Observational Drug Effect Studies (CNODES) Investigators. Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis. *Clin J Am Soc Nephrol*. 2015 Oct 7;10(10):1716-22. PMID: 26231193

Filion, Kristian

--Atallah R, **Filion KB**, Wakil SM, Joseph L, Genest J, Pilote L, Poirier P, Rinfret S, Schiffrin E, Eisenberg MJ. Long-term effects of 4 popular diets on weight loss and cardiovascular risk factors: a systematic review of randomized controlled trials. *Circ Cardiovasc Qual Outcomes* 2014; 7:815-27

--**Filion KB**, Agarwal AK, Ballantyne CM, Hoogeveen RC, Huxley RR, Loehr LR, Nambi V, Soliman EZ, Alonso, A. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study. *Am Heart J* 2015; 169:31-8

--** uma L, **Filion KB**, Atallah R, Eberg M, Eisenberg MJ. A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists. *Am J Cardiol* 2015; 115:533-41

--*Touma L, **Filion KB**, *Sterling LH, Atallah R, Windle SB, **Eisenberg MJ**. Stent-Retrievers for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *JAMA Neurol* 2016; doi:10.1001/jamaneurol.2015.4441 [Epub]

--Mancini JG, **Filion KB**, Atallah R, **Eisenberg MJ**. Systematic Review of the Mediterranean Diet for Long-Term Weight Loss. *Am J Med* 2015; doi: 10.1016/j.amjmed.2015.11.028 [Epub]

--Faillie JL, **Filion KB**, Patenaude V, Ernst P, Azoulay L. DPP-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. *Diabetes Obes Metab*. 2015; 17:379-85

--** Sterling LH, Windle SB, **Filion KB**, Eisenberg MJ. Pharmacological management strategies for stroke prevention following transcatheter aortic valve replacement: a systematic review. *Int J Cardiol* 2015; 191:303-311

--Tremblay MC, Pluye P, Gore G, Granikov V, **Filion KB**, Eisenberg MJ. Regulation profiles of e-cigarettes in the United States: A critical review with qualitative synthesis. *BMC Med* 2015; 13:130

--Rose A, **Filion KB**, Eisenberg MJ, Franck C. Electronic cigarettes: a comparison of national regulatory approaches. *Can J Public Health* 2015; 106:e450-e453

--Renoux C, Dellaniello S, Saarela O, **Filion KB**, Boivin JF. Antiepileptic drugs and the risk of ischemic stroke and myocardial infarction. *BMJ Open* 2015;5:e008365-S108

--** Lu C, **Filion KB**, Eisenberg MJ. The safety and efficacy of ABSORB bioresorbable vascular scaffold: a systematic review. *Clin Cardiol*. 2015 Sep 23. doi: 10. 1002/clc. 22451. [Epub ahead of print]

--**Filion KB**, Eberg M, **Ernst P**. Confounding by formulary restriction in pharmacoepidemiologic research. *Pharmacoepidemiol Drug Saf*. 2015 Dec 9. doi: 10. 1002/pds. 3923. [Epub ahead of print]

Galiatsatos, Polymnia

--Schiavi A, Lavigne J, Turcotte R, Kasprzak L, Dumas N, Chong G, Freeman C, Alameldin M,

--**Galiatsatos P**, Palma L, Foulkes WD. Using a family history questionnaire to identify adult patients with an increased genetic risk for sarcoma, *Current Oncology* 2015;22:317-325.

--**Galiatsatos P**. The Case of the Pink Polka-Dots. *The Canadian Journal of Diagnosis*.

Gatignol, Anne

--Daniels SM, Sinck L, Ward NJ, Melendez-Peña CE, Scarborough RJ, Azar IRance E, Daher A, Pang K-M, Rossi JJ and **Gatignol A**. HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs. *RNA Biology*. 12:123-135, 2015

--Scarborough RJ, Adams KL, Daher A and **Gatignol A**. Effective inhibition of HIV-1 production by short hairpin RNAs and small interfering RNAs targeting a highly conserved site in HIV-1 Gag RNA is optimized by evaluating alternative length formats. *Antimicrob. Agents Chemother*. 59:5297-305, 2015

--Scarborough RJ, and **Gatignol A**. HIV and Ribozymes. *Adv. Exp. Med. Biol*. 848:97-116, 2015

--**Gatignol A**. PKR and HIV replication. In: *Encyclopedia of AIDS*, section “Cellular restriction Factors”, Publisher: Springer Science and Business Media, New York. Eds: T. Hope, D. D. Richman, M. Stevenson, 2015, pp1-6. DOI: 10.1007/978-1-4614-9610-6_387-1. ISBN 978-1-4614-9610-6.

Greenaway, Christina

--Leder K, Steffen R, Cramer JP, **Greenaway C**. Risk assessment in travel medicine: How to obtain, interpret, and use risk data for informing pre-travel advice. *J Travel Med*. 2015; 22(1):13-20.

--Steffen R, Behrens RH, Hill DR, **Greenaway C**, Leder K. Vaccine-preventable travel health risks: What is the evidence—What are the gaps? *J of Travel Med*. 2015; 22(1):1-12.

--Bauer M, Ahmed S, Benedetti A, **Greenaway C**, Lalli M, Leavens A, Menzies R, Vadeboncoeur C, Vissandjée B, Wynne A, Schwartzman K. Health-related quality of life and tuberculosis: a longitudinal cohort study. *Health Qual Life Outcomes*. 2015; 13(1):65.

--Yeung MW, Young J, Moodie EEM, Rollet-Kurhajec KC, Schwartzman K, **Greenaway C**, Cooper C, Cox J, Gill MJ, Hull M, Walmsley S, Klein MB, for the Canadian Coinfection Cohort Study Investigators. Changes in quality of life, health care use, and substance use in HIV/hepatitis C coinfecting patients after hepatitis C therapy: a prospective cohort study. *HIV Clin Trials*. 2015; 16(3):100-110.

--Bauer M, Ahmed S, Benedetti A, **Greenaway C**, Lalli M, Leavens A, Menzies D, Vadeboncoeur C, Vissandjée B, Wynne A, Schwartzman K. The impact of tuberculosis on health utility: a longitudinal cohort study. *Qual Life Res*. 2015; 24(6):1337-1349.

--**Greenaway C***, Ma A, Kloda L, Klein M, Cnossen S, Schwartzer G, Shrier I. The Seroprevalence of Hepatitis C in the Migrant Population: A Systematic Review and Meta-Analysis. *PlosOne*, 2015 Dec 9;10(12):e0144567doi: 10.1371/journal.pone.0144567

--Pottie K, **Greenaway C**, Hassan G, Hui C, Kirmayer LJ. Caring for a newly arrived Syrian refugee family. *CMAJ*, 2015 In Press

Gyger, Genevieve

--**Gyger G**, Baron M. Systemic Sclerosis: Gastrointestinal Disease and Its Management. Rheumatic diseases clinics of North America 2015;41:459-73.

Hirsch, Andrew

--Robitaille C, Dajczman E, **Hirsch A**, Small D, Ernst P, Porubska D, Palayew M. Implementation of a targeted screening program to detect airflow obstruction suggestive of chronic obstructive pulmonary disease within a presurgical screening clinic. Can Respir J. 2015 Jul-Aug;22(4):209-14. PMID: 25961279

Hoffer, L John

--**Hoffer LJ**, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J, Cohen V, Small D, Miller WH Jr. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS ONE 2015.10:e0120228

--**Hoffer LJ**, Bistrrian BR. Approach to the patient and differential diagnosis. IN: Bier D, ed. Nutrition for the Primary Care Provider. Basel: Karger, pp 87-93, 2015

--**Hoffer LJ**, Bistrrian BR. Energy deficit is clinically relevant for critically ill patients: Con! Intensive Care Med 41: 339-341, 2015

--Bistrrian BR, **Hoffer LJ**, Driscoll DF. Enteral and parenteral nutrition therapy. IN: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine, 19 ed. McGraw Hill, Ch 98e p 465, 2015

Hudson, Marie

--Bernatsky S, Smargiassi A, Johnson M, Kaplan GG, Barnabe C, Svenson L, Brand A, Bertazzon S, **Hudson M**, Clarke AE, Fortin PR, Edworthy S, Belisle P, Joseph L. Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. Environmental research 2015;140:474-8.

--Frech T, **Hudson M**. Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature. Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S179-81. Epub 2015 Sep 1.

--Alhajeri H, **Hudson M**, Fritzler M, Pope J, Tatibouet S, Markland J, Robinson D, Jones N, Khalidi N, Docherty P, Kaminska E, Masetto A, Sutton E, Mathieu JP, Ligier S, Grodzicky T, LeClercq S, Thorne C, Gyger G, Smith D, Fortin PR, Larche M, Baron M. 2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. Arthritis care & research 2015;67:582-7.

--**Hudson M**. Scleroderma renal crisis. Current opinion in rheumatology 2015;27:549-54.

--**Hudson M**, Baron M, Colmegna I, Bernatsky S, Klein Oros K, Pastinen T, Greenwood C. Novel approaches to discovery of biomarkers in rheumatoid arthritis: comment on the article by Oswald et al. Arthritis & rheumatology (Hoboken, NJ) 2015;67:2276-7.

--Jewett LR, Malcarne VL, Kwakkenbos L, Harcourt D, Rumsey N, Korner A, Steele RJ, **Hudson M**, Baron M, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD. Development and Validation of the Body Concealment Scale for Scleroderma (BCSS). *Arthritis care & research* 2015.

--Levis B, Rice DB, Kwakkenbos L, Steele RJ, Hagedoorn M, **Hudson M**, Baron M, Thombs BD. Using Marital Status and Continuous Marital Satisfaction Ratings to Predict Depressive Symptoms in Married and Unmarried Women with Systemic Sclerosis: A Canadian Scleroderma Research Group Study. *Arthritis care & research* 2015.

--Liang L, Willis-Owen SA, Laprise C, Wong KC, Davies GA, Hudson TJ, Binia A, Hopkin JM, Yang IV, Grundberg E, Busche S, **Hudson M**, Ronnblom L, Pastinen TM, Schwartz DA, Lathrop GM, Moffatt MF, Cookson WO. An epigenome-wide association study of total serum immunoglobulin E concentration. *Nature* 2015;520:670-4.

--Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, **Hudson M**, Inanç M, Rothfield NF, Nash PT, Furie RA, Sénécal JL, Chandran V, Burgos-Vargas R, Ramsey-Goldman R, Pope JE. Treatment algorithms in systemic lupus erythematosus. *Arthritis Care Res (Hoboken)*. 2015 Mar 16. doi: 10.1002/acr.22589.

--Oros Klein K, Grinek S, Bernatsky S, Bouchard L, Ciampi A, Colmegna I, Fortin JP, Gao L, Hivert MF, **Hudson M**, Kobor MS, Labbe A, MacIsaac JL, Meaney MJ, Morin AM, O'Donnell KJ, Pastinen T, Van Ijzendoorn MH, Voisin G, Greenwood CM. funtooNorm: an R package for normalization of DNA methylation data when there are multiple cell or tissue types. *Bioinformatics (Oxford, England)* 2015.

--Pope JE, Rothfield NF, Ramsey-Goldman R, Smith CD, Bernatsky SR, Furie RA, **Hudson M**, Burgos-Vargas R, Senecal JL, Inanc M, van Vollenhoven RF, Chandran V, Nash PT, Muangchan C. Hydroxychloroquine treatment in SLE. *Arthritis care & research* 2015.

--Riehm KE, Kwakkenbos L, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Poiraudau S, Nielsen K, Baron M, Frech T, **Hudson M**, Pope J, Sauve M, Suarez-Almazor ME, Wigley FM, Thombs BD. Validation of the Self-Efficacy for Managing Chronic Disease (SEMCD) Scale: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *Arthritis care & research* 2015.

--Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, **Hudson M**, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody-negative systemic sclerosis. *Seminars in arthritis and rheumatism* 2015;44:680-6.

--Srivastava N, **Hudson M**, Tatibouet S, Wang M, Baron M, Fritzler MJ. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. *Seminars in arthritis and rheumatism* 2015;45:184-9.

--Thombs BD, Jewett LR, Kwakkenbos L, **Hudson M**, Baron M. Major depression diagnoses among patients with systemic sclerosis: baseline and one-month followup. *Arthritis care & research* 2015;67:411-6.

--Wodkowski M, **Hudson M**, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M, Baron M, Fritzler MJ. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. *Autoimmunity* 2015;48:542-51.

--Wodkowski M, **Hudson M**, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ. Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574

systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. *Clinical and experimental rheumatology* 2015;33:S131-5.

Jago, Thomas

--Kaitlin Giles, Vera Mazurak, Chen Guan, **R Thomas Jago**. Diet composition as a source of variance in experimental animal models of cancer cachexia. *J Cachexia, Sarcopenia and Muscle*. DOI: 10.1002/jcsm.12058

--Gouspillou G, Scheede-Bergdahl C, Spendiff S, Vuda M, Meehan B, Mlynarski H, Archer-Lahlou E, Sgarioto N, Purves-Smith FM, Konokhova Y, Rak J, Chevalier S, Taivassalo T, Hepple RT, **Jago RT**. Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle. *Sci Rep* 5, 8717: DOI: 10.1038/srep08717, 2015

--Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, Strasser F, Thoresen L, **Jago RT**, Chasen M, Lundholm K, Bosaeus I, Fearon KH, Baracos VE. Diagnostic criteria for the classification of cancer-associated weight loss. *J Clin Oncol* 33(1), 90–99, 2015

Johnson, Nathalie

--Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J, Boyle M, Mottok A, Ennishi D, **Johnson NA**, Steidl C, Connors JM, Morin RD, Gascoyne RD, Marra MA. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. *Genome Biol*. 2015 Jan 29;16:18.

--Nielsen TH, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AM, Oros KK, Krumsiek J, Crump M, Morin RD, Cerchiatti L, **Johnson NA**, Petrogiannis-Haliotis T, Miller WH Jr, **Assouline SE**, Mann KK. Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials. *Cancer Epidemiol Biomarkers Prev*. 2014 Dec;23(12):2688-93.

--Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, Drake M, Hu S, Ding J, Ha G, Scott DW, Kridel R, Bashashati A, Rogic S, **Johnson N**, Morin RD, Rimsza LM, Sehn L, Connors JM, Marra MA, Gascoyne RD, Shah SP, Steidl C.K " An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. *Blood*. 2015 Feb 5;125(6):959-66.

Joyal, Dominique

--Fox BD, **Joyal D**, Schlesinger RD, **Eisenberg MJ**, Langleben D. Evaluation of the Microstat™ sublingual PCO2 monitor in ambulatory patients. *J Clin Monit Comput* 2015; doi: 10.1007/s10877-015-9686-7. [Epub]

Kahn, Susan R

--*Rabinovich A, *Cohen JM, Cushman M, **Kahn SR** for the BioSOX Investigators. Association between inflammation biomarkers, anatomical extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis *Journal of Vascular Surgery* 2015 October, 3(4):347–353.e1.

--*Cohen JM, **Kahn SR**, Platt RW, Basso O, Evans RW, Kramer MS. Small for gestational age birth and maternal plasma antioxidant levels in midgestation: a nested case control study. *BJOG* 2015 Sep;122(10):1313-1321.

--*Cohen JM, Kramer MS, Platt RW, Basso O, Evans RW, **Kahn SR**. The association between maternal antioxidant levels in midpregnancy and preeclampsia. *Am J Obstet Gynecol*. 2015 Nov;213(5):695.e1-695.e13.

--*Cohen JM, Beddaoui M, Kramer MS, Platt RW, Basso O, **Kahn SR**. Maternal antioxidant levels in pregnancy and preeclampsia or small for gestational age birth: A Systematic Review and Meta-Analysis. *PLoS One*. 2015 Aug 6;10(8):e0135192.

--*Rabinovich A, *Cohen JM, **Kahn SR**. Predictive value of markers of inflammation in the postthrombotic syndrome: a systematic review. *Inflammatory biomarkers and PTS. Thromb Res*. 2015 Jun;136:289–297.

--Lakoski SG, Savage PD, Berkman AM, Penalosa L, Crocker A, Ades PA, **Kahn SR**, Cushman M. The Safety and Efficacy of Early Initiation Exercise Training After Acute Venous Thromboembolism: A Randomized Clinical Trial. *J Thromb Haemost* 2015 Jul;13(7):1238-1244.

--*Rabinovich A, *Cohen JM, Cushman M, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Lazo-Langner A, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Ginsberg JS, **Kahn SR**. Inflammation Markers and Their Trajectories after Deep Vein Thrombosis in relation to Risk of Postthrombotic Syndrome. *J Thromb Haemost* 2015 Mar;13(3):398-408.

--**Kahn SR** and Shapiro S. Response. *Clin Trials* 2015 Apr;12(2):178.

--**Kahn SR**, Shapiro S, Ginsberg J. Rebuttal to Partsch et al. "Pain relief by compression in acute DVT. A critique of Kahn et al." *Thromb Haemost* 2015;113:906. *Thromb Haemost*. 2015 Mar 30;113(4):907.

--Rodger MA, Hague WM, Kingdom J, **Kahn SR**, Wells PS. Dalteparin for pregnant women with thrombophilia - authors' reply. *Lancet*. 2015 Feb 21;385(9969):690.

--Rodger MA, Phillips P, **Kahn SR**, James AH, Konkle BA for the PROSPER Investigators. Low-molecular-weight heparin to prevent postpartum venous thromboembolism A pilot randomised placebo-controlled trial. *Thromb Haemost* 2015;113(1):212-216.

--*Galanaud J-Ph. and **Kahn SR**. Chapitre 12: Le syndrome post-thrombotique. La maladie veineuse chronique, pp. 171-181. Elsevier Masson (Ed.), 7 oct. 2015.

--*Galanaud J-P and **Kahn SR**. Chapitre 30: Traitement de la thrombose veineuse profonde. La compression élastique. La maladie thrombo-embolique veineuse, pp 265-271. Elsevier Masson (Ed.), 25 mars 2015.

Karaplis, Andrew

--Jiang M, Chen G, Lu N, Zhang Y, Jin S, **Karaplis AC**, Goltzman D, Miao D. Deficiency of the parathyroid hormone-related peptide nuclear localization and carboxyl terminal sequences leads to premature skin ageing partially mediated by the upregulation of p27. *Exp Dermatol*. 2015 Nov;24(11):847-52. doi:10.1111/exd.12789

--Hirai T, Kobayashi T, Nishimori S, **Karaplis AC**, Goltzman D, Kronenberg HM. Bone Is a Major Target of PTH/PTHrP receptor signaling in regulation of fetal blood calcium homeostasis. *Endocrinology*. 2015 Aug;156(8):2774-80. doi:10.1210/en.2014-1835.

--Zhu M, Zhang J, Dong Z, Zhang Y, Wang R, **Karaplis AC**, Goltzman D, Miao D. The p27 pathway modulates the regulation of skeletal growth and osteoblastic bone formation by parathyroid hormone-related peptide. *J Bone Miner Res*. 2015 Nov;30(11):1969-79. doi:10.1002/jbmr.2544.

Kleiman, Lawrence

--Wei M, Zhao X, Liu M, Huang Z, Xiao Y, Niu M, Shao Y and **Kleiman L**. Inhibition of HIV-1 assembly by coiled-coil domain containing protein 8 in human cells. (2015) *Sci. Rep.* Oct. 1.5: 14724. doi: 10.1036/srep14724.

--Seif E, Niu M, and **Kleiman L**. In virio SHAPE analysis of tRNA(Lys3) annealing to HIV-1 genomic RNA in wild type and protease-deficient virus. (2015) *Retrovirology* 12: 40. doi: 10.1186/s12977-015-171-7 PMID: 25981241

Knecht, Hans

--Righolt CH, **Knecht H**, Mai S. DNA Super resolution Structure of Reed-Sternberg Cells Differs Between Long Lasting Remission Versus Relapsing Hodgkin's Lymphoma Patients. *J Cell Biochem.*2015 Dec 7. doi: 10.1002/jcb.25456. [Epub ahead of print]

--Lajoie V, Lemieux B, Sawan B, Lichtensztejn D, Lichtensztejn Z, Wellinger R, Mai S, **Knecht H**. LMP1 mediates multi-nuclearity through down regulation of shelter in proteins and formation of telomeric aggregates. *Blood.* 2015 Mar 26;125(13):2101-10. This manuscript got the Cover Caption of the journal and was chosen as paper of the month at the LDI.

Langleben, David

--**Langleben D**, Orfanos SE, Giovinazzo M, Schlesinger RD, Hirsch AM, Blenkhorn F, Lesenko L, Armaganidis A, Catravas JD. Acute vasodilator responsiveness and microvascular recruitment in idiopathic pulmonary arterial hypertension. *Ann Intern Med.* 2015;162:154-6.

--**Langleben D**, Galie N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. *J Heart Lung Transplant.* 2015;34:338-47.

--Rubin LJ, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh A, **Langleben D**, Fritsch A, Menezes F, Davie N, Ghofrani HA. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). *Eur Respir J* 2015;45:1314-1322.

--Granton J, **Langleben D**, Kutryk MB, Camack N, Galipeau J, Courtman DW, Stewart DJ. Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. *Circ Res* 2015;117:645-54.

--Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, **Langleben D**, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med* 2015;192:1345-54.

LeBlanc, Andrea

--Rouget R, **LeBlanc AC**: Phosphorylation exacerbates aggregation and fibrillization of familial prion protein mutants. [CIHR MOP102738 and NIH R21] *Journal of Biological Chemistry* 2015 Jan 8. pii: jbc.M114.630699. [Epub ahead of print]

--Vikas Kaushal, Rebecca Dye, Bénédicte Foveau, Prateep Pakavathkumar, Bradley Hyman, Bernardino Ghetti, Beverly H. Koller, **Andrea C. LeBlanc**. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated

Caspase-6 activation. *Cell Death Differ*. 2015 Mar 6. doi: 10.1038/cdd.2015.16. [Epub ahead of print]. [MOP 81146-CIHR Casp6] 2015

-- Pakavathkumar P*, Sharma G*, Kaushal V, **LeBlanc AC**: Methylene blue inhibits the activity of Caspase-6. *Scientific Report* – 5:13730. doi: 10.1038/srep13730 [MOP 81146-CIHR Casp6] * share first co-authorship

--Peters S, MA Dery, **LeBlanc AC**: Familial prion protein mutants inhibit Hrd1-mediated retrotranslocation of misfolded proteins. *Human Molecular Genetics* 2016 in press [CIHR MOP89376 and MOP102738].

Lehoux, Stephanie

--**Lehoux S**, Jones EA. Shear stress, arterial identity and atherosclerosis. *Thromb Haemost*. 2015, 115: [Epub ahead of print]

--Lemaire M, Negro Silva LF, Lemarié CA, Bolt AM, Flores Molina M, Krohn RM, Smits JE, **Lehoux S**, Mann KK. Arsenic exposure increases monocyte adhesion to the vascular endothelium, a pro-atherogenic mechanism. *PLoS One*. 2015, 10:e0136592

--Ait-Oufella H, Bourcier S, **Lehoux S**, Guidet B. Microcirculatory disorders during septic shock. *Curr Opin Crit Care*. 2015, 21:271-5

--Le Gallic C, Phalente Y, Manens L, Dublineau I, Benderitter M, Gueguen Y, **Lehoux S***, Ebrahimiyan TG*. Chronic internal exposure to low dose 137Cs induces positive impact on the stability of atherosclerotic plaques by reducing inflammation in ApoE^{-/-} mice. *PLoS One* 2015,10:e0128539. *co-senior author

--Beaudoin M, Gupta RM, Won HH, Lo KS, Do R, Henderson CA, Lavoie-St-Amour C, Langlois S, Rivas D, **Lehoux S**, Kathiresan S, Tardif JC, Musunuru K, Lettre G. Myocardial infarction-associated snp at 6p24 interferes with mef2 binding and associates with PHACTR1 expression levels in human coronary arteries. *Arterioscler Thromb Vasc Biol*. 2015, 35:1472-9

--Jahnsen ED, Trindade A, Zaun HC, **Lehoux S**, Duarte A, Jones EA. Notch1 is pan-endothelial at the onset of flow and regulated by flow. *Plos ONE*. 2015, 10:e0122622.

Levinoff, Elise

--Kabeshova A, Launay CP, Gromov VA, Fantino B, **Levinoff EJ**, Allali G, Beauchet O. Falling in the elderly: Do statistical models matter for performance criteria of fall prediction? Results from two large population-based studies. *Eur J Intern Med*. 2015 Dec 10. [Epub ahead of print] *Eur J. Intern Med*. 2016 Jan;27:48-56. doi: 10.1016/j.ejim.2015.11.019. Epub 2015 Dec 10

Liang, Chen

--Zhu W, Lei R, Le Duff Y, Li J, Guo F, Wainberg M and **Liang C** . The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. *Retrovirology* 2015 Feb 27;12:22. doi: 10.1186/s12977-015-0150-z.

--Jia R, Ding S, Pan Q, Liu S, Qiao W and **Liang C** . The C-terminal sequence of IFITM1 regulates its anti-HIV-1 activity. *PLoS One* 2015 Mar 4;10(3):e0118794. doi: 10.1371/journal.pone.0118794. eCollection 2015.

--Liu Z, Pan Q, Liang Z, Qiao Q, Cen S and **Liang C** . The highly polymorphic cyclophilin A-binding loop in HIV-1 capsid modulates viral resistance to MxB. *Retrovirology* 2015 Jan 9;12:1. doi: 10.1186/s12977-014-0129-1.

--Qian J, Le Duff Y, Wang Y, Pan Q, Ding S, Zheng Y, Liu S and **Liang C** . Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins. *Virology* 2015 Jan 1;474:10-8. doi: 10.1016/j.virol.2014.10.015. Epub 2014 Nov 7.

--Mi Z, Ding J, Zhang Q, Zhao J, Ma L, Yu H, Liu Z, Shan G, Li X, Zhou J, Wei T, Zhang L, Guo F, **Liang C**, and Cen S. A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2. *Scientific Reports* 2015 Dec 16;5:18499. doi: 10.1038/srep18499..

--Yu J, Li M, Wilkins J, Ding S, Swartz T, Esposito A, Zheng Y, Freed E, **Liang C**, Chen B, and Liu S. IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein. *Cell Reports* 2015 Oct 6;13(1):145-56. doi: 10.1016/j.celrep.2015.08.055. Epub 2015 Sep 17.

--Hu S, Li J, Xu F, Mei S, Le Duff Y, Yin L, Pang X, Cen S, Jin Q, **Liang C** and Guo F. SAMHD1 inhibits LINE-1 retrotransposition by promoting stress granule formation. *PLoS Genet* 2015 Jul 2;11(7):e1005367. doi: 10.1371/journal.pgen.1005367. eCollection 2015 Jul.

--Li J, Xu F, Hu S, Zhou J, Mei S, Zhao X, Cen S, Jin Q, **Liang C** and Guo F. Characterization of the interactions between SIVrcm Vpx and red-capped mangabey SAMHD1. *Biochem J.* 2015 Jun 1;468(2):303-13. doi: 10.1042/BJ20141331.

--Li K, Jia R, Li M, Zheng Y, Miao C, Yao Y, Geng Y, Qiao W, Albritton L, **Liang C** and Liu S. A sorting signal suppresses IFITM1 restriction of viral entry. *J Biol. Chem.* 2015 Feb 13;290(7):4248-59. doi: 10.1074/jbc.M114.630780. Epub 2014 Dec 19.

Lipman, Mark

--Dubrofsky L, **Lipman ML**, Nessim SJ. Make Your Diagnosis: Hypercalcemia in a renal transplant recipient. *Kidney Int* 2015 Nov; 88(5): 1207-8.

--Nguyen M-T, Fryml E, Sahakian SK, Liu S, Cantarovich M, Lipman M, Tchervenkov JI, Paraskevas S. Pre-transplant recipient circulating CD4+CD127-TNFR2+ Treg: a surrogate of Treg suppressive function and predictor of delayed and slow graft function after kidney transplantation. *Transplantation*. 2015 Oct 1. [Epub ahead of print] PMID:26425877

Lin, Rongtuan

--Chiang C, Beljanski V, Yin K, Olagnier D, Ben Yebdri F, Steel C, Goulet ML, DeFilippis VR, Streblov DN, Haddad EK, Trautmann L, Ross T, **Lin R**, Hiscott J. Sequence-specific modifications enhance the broad spectrum antiviral response activated by RIG-I agonists. *J Virol.* 2015 Aug;89(15):8011-25. doi: 10.1128/JVI.00845-15. Epub 2015 May 27. PMID:26018150.

--Goubau D, van der Veen AG, Chakravarty P, **Lin R**, Rogers N, Rehwinkel J, Deddouche S, Rosewell I, Hiscott J, Reis E Sousa-C C. Mouse superkiller-2-like helicase DDX60 is dispensable for type I IFN induction and immunity to multiple viruses. *Eur J Immunol.* 2015 Dec;45(12):3386-403. doi: 10.1002/eji.201545794. Epub 2015 Oct 12. PMID:26457795.

--Li S, Pinard M, Wang Y, Yang L, **Lin R**, Hiscott J, Su B, Brodt P. Crosstalk between the TNF and IGF pathways enhances NF- κ B activation and signaling in cancer cells. *Growth Horm IGF Res.* 2015 Oct;25(5):253-61. doi: 10.1016/j.ghir.2015.07.008. Epub 2015 Jul 20. PMID:26239406.

--Lingel A, Ehlers E, Wang Q, Cao M, Wood C, **Lin R**, Zhang L. Kaposi's sarcoma-associated herpesvirus reduces cellular myeloid differentiation primary response gene-88 (MyD88) expression via modulation of its RNA. *J Virol.* 2015 Oct 14;90(1):180-8. doi: 10.1128/JVI.02342-15. PMID:26468534.

--Wang P, Zhu S, Yang L, Cui S, Pan W, Jackson R, Zheng Y, Rongvaux A, Sun Q, Yang G, Gao S, **Lin R**, You F, Flavell R, Fikrig E. Nlrp6 regulates intestinal antiviral innate immunity. *Science.* 2015 Nov 13;350(6262):826-30. doi: 10.1126/science.aab3145. Epub 2015 Oct 22. PMID:26494172

Longtin, Yves

--Brukner I, **Longtin Y**, Oughton M, Forgetta V, Dascal A. Assay for estimating total bacterial load: relative qPCR normalisation of bacterial load with associated clinical implications. *Diagn Microbiol Infect Dis.* 2015 Sep;83(1):1-6. doi: 10.1016/j.diagmicrobio.2015.04.005. Epub 2015 May 2.

--Bonifait L, Charlebois R, Vimont A, Turgeon N, Veillette M, **Longtin Y**, Jean J, Duchaine C. Detection and quantification of airborne norovirus during outbreaks in healthcare settings. *Clin Infect Dis.* 2015 Aug 1;61(3):299-304.

Mann, Koren

--AM Bolt, V Sabourin, MF Molina, AM Police, LF Negro Silva, D Plourde, M Lemaire, J Ursini-Siegel, **KK Mann**. Tungsten targets the tumor microenvironment to enhance breast cancer metastasis. *Toxicol Sci.* Jan;143(1):165-77, 2015.

--Ebrahimian T, Simon D, Lemarie CA, Heidari M, **Mann KK**, Wassmann S, **Lehoux S**. Absence of Four-and-a-Half LIM domain protein 2 decreases atherosclerosis in ApoE^{-/-} mice. *Arterioscler Thromb Vasc Biol.* 2015, 35:1190-7.

--BB Patel, A Kasneci, AM Bolt, V Di Lalla, MR Di Iorio, M Raad, **KK Mann** and LE Chalifour. Chronic exposure to bisphenol A reduces successful cardiac remodeling after an experimental myocardial infarction in C57bl/6n mice. *Toxicological Sciences* 146(1):101-15, 2015.

Miller, Mark

--Le Saux N, Gravel D, Mulvey M, Moore D, Langley JM, Richardson S, Quach C, Choi KB, **Miller M**, Katz K, and the Canadian Nosocomial Infection Surveillance Program. Healthcare Associated Clostridium difficile Infections and Strain Diversity in Pediatric Hospitals in the Canadian Nosocomial Infection Surveillance Program: 2007-2011. *J Ped Infect Dis* first published online March 19, 2015
doi:10.1093/jpids/piv011

--Weiss K, Louie T, **Miller MA**, Mullane K, Crook DW, Gorbach SL. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhea. *BMJ Open Gastro* 2015;2:e000028

--Hernández-García R, Garza-González E, **Miller M**, Arteaga-Muller G, Galván-de Los Santos AM, Camacho-Ortiz A. Application of the ATLAS score for evaluating the severity of Clostridium difficile infection in teaching hospitals in Mexico. *Brazilian Journal Infect Dis.* 2015;19:399-402

--Popiel K, Gheorghe R, Eastmond J, **Miller M**. Usefulness of Adjunctive Fecal Calprotectin and Serum Procalcitonin in Individuals with a Positive *C. difficile* Toxin Gene Polymerase Chain Reaction Assay. *J Clin Microbiol* 2015;53:3667–3669

Miller, Wilson H. Jr.

--Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, **Miller WH Jr**, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. *J Immunother Cancer*. 3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015.

--Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler L, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, **Miller WH Jr.**, Zager J S, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, and Coffin R. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. *JCO*. 33(25):2780-8, 2015.

--Petterson F, del Rincon SV, Emond A, Huor B, Ngan E, Ng J, Dobocan MC, Peter Siegel, and **Miller WH Jr**. Genetic and Pharmacologic Inhibition of eIF4E Reduces Breast Cancer Cell Migration, Invasion, and Metastasis. *Cancer Research* 75(6):1102-12, 2015.

--Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, and Ribas A. ;KEYNOTE-006 investigators Carlino MS, Cebon J, Hersey P, Long G, McNeil C, Millward M, Walpole E, Höller C, Kehrer H, Richtig E, Schmuth M, Baurain JF, Neyns B, Wolter P, Butler M, McWhirter E, **Miller WH Jr**, Petrella T, Acevedo A, Caglevic C, Morales L, Sanchez J, Yepes A, Zambrano AR, Avril MF, Dutriaux C, Grob JJ, Guilot B, Lacour JP, Leccia MT, Legoupil D, Lebbe C, Machet L, Mortier L, Robert C, Berking C, Loquai C, Mohr P, Schadendorf D, Utikal J, Bar-Sela G, Lotem M, Schachter J, Blank C, Barrow C, Fitzharris B, Kersten C, Nyakas M, Straume O, Arance A, Berrocal A, Cortes J, Espinosa E, Lopez-Martin J, Martin-Algarra S, Masucci G, Papworth K, Ullenhag G, Brown E, Chao D, Evans T, Larkin J, Lorigan P, Middleton M, Skaria S, Steven N, Agarwala S, Bhatia S, Daud A, Gangadhar T, Gonzalez R, Hamid O, Kumar P, Kuzel T, Lutzky J, O'Day S, Perry D, Pecora A, Puzanov I, Ribas A, Slezak K, Sznol M, Tarhini A, Weiss G. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med* 372:2521-2532, 2015.

--Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, **Miller WH Jr**, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*.16(4):375-84, 2015.

--Zhan Y, Dahabieh MS, Dobocan MC, Boutchou M-N, Goncalves C, Liu LS, Petterson F, Rajakumarm A, Topisirovic I, van Kempen L, del Rincón SV, **Miller WH Jr**. The role of eIF4E in response and acquired resistance to vemurafenib in melanoma. *Journal Of Investigative Dermatology*. 135(5):1368-76, 2015.

Monette, Johanne

--Voyer P, Champoux N, Desrosiers J, Landreville P, McCusker J, **Monette J**, Savoie M, Richard S, Carmichael PH. Recognizing Acute Delirium as part of your Routine (RADAR): a validation study. *BMC Nursing*. 2015 Apr 1;14:19. doi: 10.1186/s12912-015-0070-1. eCollection 2015.

--Kroger E, Wilchesky M, Marcotte M, Voyer P, Morin M, Champoux N, **Monette J**, Aubin M, Durand P, Verreault R, Arcand M. Medication use among Nursing Home Residents with Severe dementia: Identifying Categories of Appropriateness and Elements of a Successful Intervention. *Journal of the American Medical Directors Association*. 2015 Jul 1;16(7):629.e1-629.e17. doi: 10.1016/j.jamda.2015.04.002. Epub 2015 May 13.

--Puts M, Tapscott B, Fitch M, Howell D, **Monette J**, Wan-Chow-Wah D, Krzyzanowska M, Leighl N, Springall E, Alibhai S. A Systematic Review of Factors Influencing Older Adults' Hypothetical Treatment Decisions. *Oncology & Hematology Review*. 2015 June;11(1):19–33 DOI: 10.17925/OHR.2015.11.01.19

Morais, Jose A

--Chevalier S, Burgos SA, **Morais JA**, Gougeon R, Bassil M, Lamarche M, Marliss EB. Protein and glucose metabolic responses to hyperinsulinemia, hyperglycemia and hyperaminoacidemia in obese men. *Obesity* 2015;23:351-8. doi: 10.1002/oby.20943.

--Gougeon L, Payette H, **Morais JA**, Gaudreau P, Shatenstein B, Gray-Donald K. Dietary patterns and incidence of depression in a cohort of community-dwelling older Canadians. *J Nutr Health Aging* 2015. Apr;19(4):431-6. doi: 10.1007/s12603-014-0562-9.

--St-Jean Pelletier F, Pion CH, Lemieux F, Leduc-Gaudet JP, Barbat-Artigas S, Sgarioto N, Gaudreau P, Hepple RT, Chevalier S, Belanger M, **Morais JA**, Aubertin-Leheudre M, Gouspillou G. Aging and Physical Activity: Effects on Human Skeletal Muscle Phenotype. *Canadian Journal of Diabetes* 04/2015; DOI: 10.1016/j.jcjd.2015.01.281

--Labonte CC, Chevalier S, Marliss EB, **Morais JA**, Gougeon R. Effect of 10% dietary protein intake on protein metabolism in type 2 diabetic adults. *Clinical Nutrition* 2015 Jan 8. pii: S0261-5614(15)00006-0. DOI: 10.1016/j.clnu.2014.12.02

--Vigano A, **Morais JA**. The elderly patient with cancer: a holistic view. *Nutrition*. 2015Apr;31(4):587-9. doi: 10.1016/j.nut.2015.01.001

--Murphy J, Chevalier S, Gougeon R, Goulet EDB, **Morais JA**. Insulin resistance of protein metabolism in obese elderly women with and without type 2 diabetes. *ExpGerontol*2015 Jun 8;69:20-26. doi: 10.1016/j.exger.2015.06.008..

--Cusson V, Payette H, Shatenstein B, Gaudreau P, **Morais JA**, Caron C. Assessing older adults' masticatory efficiency. *JAGS* 2015 Jun;63(6):1192-6. doi: 10.1111/jgs.13443. Epub2015 Jun 11

--Gosselin S, Morris M, Miller-Nesbitt A, Hoffman RS, Hayes BD, Turgeon AF, Gilfix BM, Grunbaum AM, Bania TC, Thomas SH, **Morais JA**, Graudins A, Bailey B, Mégarbane B, Calello DP, Levine M, Stellpflug SJ, Hoegberg LC, Chuang R, Stork C, Bhalla A, Rollins CJ, Lavergne V; AACT Lipid Emulsion Therapy workgroup. Methodology for AACT evidence-based recommendations on the use of lipid emulsion therapy in poisoning. *ClinToxicol (Phila)*. 2015 Jul;53(6):557-64. doi: 10.3109/15563650.2015.1052498. Epub2015 Jun 10

--Matta J, Mayo N, Dionne IJ, Gaudreau P, Fulop T, Tessier D, Gray-Donald K, Shatenstein B, Scott S, **Morais JA**. Muscle mass index and animal source of protein intake are positively associated with insulin resistance in elderly participants of the NuAge Study. *J Nutr Health Aging* (June 15 2015 DOI: 10.1007/s12603-015-0554-4)

--Rahi B, **Morais JA**, Gaudreau P, Payette H, Shatenstein B. Energy and protein intakes and their association with a decline in functional capacity among diabetic older adults from the NuAge cohort. *Eur J Nutr*. 2015 Jul 16. [Epub ahead of print]. PMID:26179475

--Shatenstein B, Gauvin L, Keller H, Richard L, Gaudreau P, Giroux F, Gray-Donald K, Jabbour M, **Morais JA**, Payette H. Individual and collective factors predicting change in diet quality over 3 years in a subset of older men and women from the NuAge Cohort. *Eur J Nutr*. 2015 Jul 14. [Epub ahead of print]. PMID:26169872

--Fuoco D, Di Tomasso J, Boulo C, Kilgour RD, **Morais JA**, Borod M, Vigano A. Male Hypogonadism in Advanced Cancer Patients: Nutritional, Functional and Quality of Life Correlates. *Ecancer9* 561/ DOI: 10.3332/ecancer.2015.561

--Laverdiere E, Payette H, Gaudreau P, **Morais JA**, Shatenstein B, Gray-Donald K. Prevalence of risk and protective factors associated with heat-related outcomes in southern Quebec: A secondary analysis of the NuAge Study. *Can J Public Health*. 2015 Jun 18;106(5):e315-21. doi: 10.17269/cjph.106.5029.

--Fulop T, McElhaney J, Pawelec G, Cohen AA, **Morais JA**, Dupuis G, Baehl S, Camous X, Witkowski JM, Larbi A. Frailty, Inflammation and Immunosenescence. *Interdiscip Top Gerontol Geriatr*. 2015;41:26-40. doi: 10.1159/000381134. Epub 2015 Jul 17.

--Power GA, Minozzo FB, Spendiff S, Filion ME, Konokhova Y, **Morais JA**, Herzog W, Hepple RT, Taivassalo T, Rassier DJ. Reduction in single muscle fiber rate of force development with aging is not attenuated in world class older masters athletes. *Am J Am J Physiol Cell Physiol*. 2015 Dec 2:ajpcell.00289.2015. doi: 10.1152/ajpcell.00289.2015.

--Gougeon L, Payette H, **Morais JA**, Gaudreau P, Shatenstein B, Gray-Donald K. Intakes of folate, vitamin B6 and B12 and risk of depression in community-dwelling older adults: the Quebec Longitudinal Study on Nutrition and Aging. *Eur J Clin Nutr*. 2015 Dec 9. doi: 10.1038/ejcn.2015.202.

Nessim, Sharon

--Fournier JP, Yin H, **Nessim SJ**, Montastruc JL, Azoulay L. Tramadol for non-cancer pain and the risk of hyponatremia. *Am J Med*. 2015 Apr;128(4):418-25

--Misra PS, Alam A, Lipman ML, **Nessim SJ**. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. *BMC Nephrol*. 2015 Aug; 16:136

--Perl J, **Nessim SJ**, Moist LM, Wald R, Na Y, Tennankore KK, Chan CT. Vascular access type and patient and technique survival in home hemodialysis patients: the Canadian Organ Replacement Register. *Am J Kidney Dis*. 2015 Sept 16 (epub ahead of print).

Panasci, Lawrence

--McLean J, Rho YS, Kuruba G, Mamo A, Gilabert M, Kavan T, **Panasci L**, Melnychuk D, Batist G, Kavan P. Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer. *Clin Colorectal Cancer*. 2015 Oct 21.pii: S1533-0028(15)00118-8. doi: 10.1016/j.clcc.2015.10.003. [Epub ahead of print]

--Shen D, Guo CC, Wang J, Qiu ZK, Sai K, Yang QY, Chen YS, Chen FR, Wang J, **Panasci L**, Chen ZP. Interferon- α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. *Oncol Rep* 2015 Nov;34(5):2715-21. doi: 10.3892/or.2015.4232. Epub 2015 Aug 27.

--Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B, Aloyz R, **Panasci L**. Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. *Front Pharmacol* 2015 Jul 22;6:147. doi: 10.3389/fphar.2015.00147. eCollection 2015.

Pantopoulos, Kostas

--Kent P, Wilkinson N, Constante M, Fillebeen C, Gkouvatsos K, Buffler M, Wagner J, Buffler M, Becker C, Schümann K, Santos MM and **Pantopoulos K**. (2015) Hfe and hemojuvelin exhibit overlapping functions for iron signaling to hepcidin, *J. Mol. Med.*, 93, 489-498 (editorial in pages 469-471).

--**Pantopoulos K**. (2015) Iron regulation of hepcidin through HFE and HJV: common or distinct pathways? *Hepatology*, 62, 1922-1923.

--**Pantopoulos K**. (2015) Tfr2 links iron metabolism and erythropoiesis, *Blood*, 125, 1055-1056.

Ponka, Premysl

--**Ponka P**, Tenenbein M, Eaton J. 2015. "Iron" (Invited Chapter; peer reviewed). In: Handbook of Toxicology of Metals, Fourth Ed (Nordberg G, Fowler B, Nordberg M, Fridberg L, Eds.), Academic Press, pp. 879-902.

--**Ponka P**, Prechal JT. 2015. Polyclonal and Hereditary Sideroblastic Anemias. In: Williams Hematology, 9th edition (Lichtman MA et al. eds.) McGraw-Hill, pp. 915-922.

--Gasiorek JJ, Mikhael M, Garcia-Santos D, Hui ST, **Ponka P**, Blank V. 2015. Thioredoxin-interacting protein regulates the differentiation of murine erythroid precursors. *Experimental Hematology*, 43: 393-403

--Fillebeen C, Gkouvatsos K, Fragoso G, Calvé A, Garcia-Santos D, Buffler M, Becker C, Schümann K, **Ponka P**, Santos MM, Pantopoulos K. 2015. Mice are poor heme absorbers and do not require intestinal Hmox1 for dietary heme iron assimilation, *Haematologica* 100:334-337.

Richard, Stephane

--*Song J. and **S. Richard**. 2015. Sam68 regulates S6K1 alternative splicing during adipogenesis. *Molecular Cellular Biology* 35:1926-39

--*Gurunathan, G., Z. Yu, Y. Coulombe, J.-Y. Masson, and **S. Richard**. 2015. Arginine methylation of hnRNPUL1 regulates interaction with NBS1 and recruitment to sites of DNA damage. *Scientific Reports* 5: 10475doi: 10.1038/srep10475.

--Zhou, J., M. Cheng, C. Boriboun, M.M. Ardehali, C. Jiang, Q. Liu, S. Han, D. A. Goukassian, Y.L. Tang, T. Zhao, M. Zhao, L. Cai, **S. Richard**, R. Kishore, and G. Qin. 2015. Inhibition of Sam68 triggers adipose tissue browning. *J Endo* 225:181-9

--*Thandapani, P./J. Song, V. Gandin, Y. Cai, S. G. Rouleau, , J.-M. Garant, F.-M. Boisvert, Z. Yu, J.-P. Perreault, I. Topisirovic, and **S. Richard**. 2015. Aven recognition of RNA G-quadruplexes regulates translation of the mixed lineage leukemia protooncogenes. *eLife* 2015;10.7554/eLife.06234

--Calibretta, S and **S. Richard**. 2015. Emerging roles of disordered sequences in RNA-binding proteins. *Trends Biochem Sci* 40:662-72

--Haines JD, D.L Fulton, **S. Richard** and G. Almazan. 2015. P38 mitogen-activated protein kinase pathway regulates genes during proliferation and differentiation in oligodendrocytes. *PLoS One* e0145843.

Richards, Brent J.

--Lakhal-Chaieb L, Oualkacha K, **Richards BJ**, Greenwood CM. A rare variant association test in family-based designs and non-normal quantitative traits. *Statistics in Medicine*, 35(6):905-21. 2016. Epub ahead of print 2015 Sep 29.

--J Huang, B Howie, S McCarthy, Y Memari, K Walter, J Min, P Danecek, G Malerba, E Trabetti, HF Zheng, G Gambaro, **JB Richards**, R Durbin, N Timpson, J Marchini, N Soranzo. Improved imputation of low frequency and rare variants using the UK10K haplotype reference panel. *Nature Communications*, 6:8111. 2015.

--LE Mokry, S Ross, OS Ahmad, V Forgetta, G Davey-Smith, A Leong, CMT Greenwood, G Thanassoulis, **JB Richards**. Vitamin D and risk of Multiple Sclerosis: a Mendelian Randomization Study. *PLoS Medicine*, 12(8):e1001866. 2015.

--HF Zheng*, V Forgetta*, YH Hsu*, K Estrada*, A Rosello-Diez*, PJ Leo*, CL Dahia*, KH Park-Min*, JH Tobias*, C Kooperberg*, A Kleinman, U Styrkarsdottir, CT Liu, C Uggla, DS Evans, CM Nielson, K Walter, U Pettersson-Kymmer, S McCarthy, J Eriksson, T Kwan, M Jhamai, K Trajanoska, Y Memari, J Min, J Huang, P Danecek, B Wilmot, R Li, WC Chou, LE Mokry, A Moayyeri, M Claussnitzer, CH Cheng, W Cheung, C Medina-Gómez, B Ge, SH Chen, K Choi, L Oei, J Fraser, R Kraaij, M Hibbs, C Gregson, D Paquette, A Hofman, C Wibom, GJ Tranah, M Marshall, B Gardiner, P Auer, L Hsu, S Ring, JY Tung, G Thorleifsson, AW Enneman, NM van Schoor, LCPGM deGroot, N vanderVelde, B Melin, JP Kemp, C Christiansen, A Sayers, Y Zhou, S Calderari, J van Rooij, C Carlson, U Peters, S Berlivet, J Dostie, AG Uitterlinden, SR Williams, C Farber, D Grinberg-, AZ LaCroix, J Haessler, DI Chasman, F Giulianini, LM Rose, PM Ridker, JA Eisman-, TV Nguyen, JR Center, XNN Garcia-Giralt, LL Launer, V Gudnason, D Mellström, L Vandenput, MK Karlsson, O Ljunggren, O Svensson, G Hallmans, F Rousseau, S Giroux, J Bussière, P Arp, F Koromani, R Prince, J Lewis, B Langdahl, AP Hermann, JEB Jensen, S Kaptoge, KT Khaw, J Reeve, MM Formosa, A Xuereb-Anastasi, K Åkesson, FE McGuigan, GG Bussière, JM Olmos, MT Zarrabeitia, JA Riancho, SH Ralston, N Alonso, X Jiang, D Goltzman, T Pastinen, E Grundberg, D Gauguier, ES Orwoll, D Karasik, G Davey-Smith, AOGC Consortium, AV Smith, K Siggeirsdottir, TB Harris, MC Zillikens, JBJ vanMeurs, U Thorsteinsdottir, MT Maurano, NJ Timpson, N Soranzo, R Durbin, SG Wilson, EE Ntzani, MA Brown, K Stefansson, DA Hinds, TS Spector, LA Cupples, C Ohlsson, C Greenwood, RD Jackson†, DW Rowe†, CA Loomis†, DM Evans†, CL Ackert-Bicknell†, AL Joyner†, EL Duncan†, DP Kiel†, F Rivadeneira†, **JB Richards**† for the GEFOS and UK10K Consortia. * and † denote equal contribution. Whole-genome sequence-based identification of EN1 as a determinant of bone density and fracture. *Nature*, 526(7571):112-7. 2015.

--K Walter*, J Min*, J Huang*, L Crooks*, Y Memari, S McCarthy, JRB Perry, C Xu, M Futema, D Lawson, V Iotchkova, S Schiffels, A Hendricks, P Danecek, R Li, J Floyd, I Barroso, SE Humphries, ME Hurles, E Zeggini, JC Barrett, V Plagnol, **JB Richards**, C Greenwood, N Timpson, R Durbin, N Soranzo. The UK10K project: rare variants in health and disease. *Nature*, 526(7571):82-90. 2015.

--Ruth KS, Campbell PJ, Chew S, Lim EM, Hadlow N, Stuckey BG, Brown SJ, Feenstra B, Joseph J, Surdulescu GL, Zheng HF, Richards JB, Murray A, Spector TD, Wilson SG, Perry JR. Genome-wide association study with 1000 genomes imputation identifies signals for nine sex-hormone-related phenotypes. *European Journal of Human Genetics*, 24(2):284-90. 2016. Epub ahead of print 2015 May 27.

--OS Ahmad, JA Morris, M Mujammami, V Forgetta, A Leong, R Li, M Turgeon, CMT Greenwood, G Thanassoulis, JB Meigs, R Sladek, **JB Richards**. Type-2 diabetes and coronary heart disease: a Mendelian randomization study. *Nature Communications*, 6:7060. 2015.

--PN. Taylor*, E Porcu*, S Chew*, PJ Campbell*, M Traglia, SJ. Brown, BH Mullin, HA Shihab, J Min, K Walter, Y Memari, J Huang, MR Barnes, JP Beilby, P Charoen, P Danecek, F Dudbridge, V Forgetta, C Greenwood, E Grundberg, AD Johnson, J Hui, EM Lim, S McCarthy, D Muddyman, V Panicker, JRB Perry, JT Bell, W Yuan, C Relton, T Gaunt, D Schlessinger, G Abecasis, F Cucca, GL Surdulescu, W Woltersdorf, E Zeggini, HF Zheng, D Toniolo, CM Dayan, S Naitza, JP Walsh, TD Spector, GD Smith, R Durbin, **JB Richards**, S Sanna, N Soranzo, NJ Timpson*, SG Wilson* and the UK10K Consortium. Whole Genome Sequence-Based Analysis of Thyroid Function. *Nature Communications*, 6:5681. 2015

--Zheng HF, Rong JJ, Liu M, Han F, Zhang XW, **Richards JB**, Wang L. Performance of Genotype Imputation for Low Frequency and Rare Variants from the 1000 Genomes. *PLoS One*, 10(1):e0116487. 2015.

--A Buil, AA Brown, T Lappalainen, A Viñuela, MN Davies, HF Zheng, **JB Richards**, D Glass, KS Small, R Durbin, TD Spector, ET Dermitzakis. Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins. *Journal of Medical Genetics*, 47(1):88-91. 2015.

Sakr, Lama

--**Sakr L**, Small D, Kasymjanova G, **Suissa S**, Ernst P. Phenotypic heterogeneity of potentially curable non-small-cell lung cancer: cohort study with cluster analysis. *J Thorac Oncol*. 2015 May;10(5):754-61

Schiffrin, Ernesto L.

--Perry CG, Freel EM, O'Dwyer P, **Schiffrin EL**, Jennings GL, Dominiczak AF, De Buyzere M. Clinico-Pathological Conference: A rare cause of severe hypertension in a young woman. *Hypertension* 2015;65:21-24. doi:10.1161/HYPERTENSIONAHA.114.04619. PMID: 25385763

--Ferrario CM, **Schiffrin EL**. Translational Success Stories: Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease. *Circ Res*. 2015; 116: 206-213. doi: 10.1161/CIRCRESAHA.116.302706. PMID: 25552697.

--Blom K, Farina S, Gomez Y-H, Campbell NRC, Hemmelgarn B, Cloutier L, Mackay DW, Dawes M, Tobe SW, Bolli P, Gelfer M, Mclean D, Bartlett G, Joseph L, Featherstone R, **Schiffrin EL**, Daskalopoulou SS. MMethods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): a Study Protocol. *Current Hypert Reports Curr Hypertens Rep*. 2015 Apr;17(4):533. Doi: 10.1007/s11906-015-0533-5. PMID: 25790798.

--Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, McKay DW, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Ramesh Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, **Schiffrin EL**, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Brian Penner S, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitza G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Stone JA, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Fournier A, Lewanczuk R, Dresser GK, Sharma M, Reid D, Benoit G, Feber J, Harris KC, Poirier L, Padwal RS. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Can J Cardiol*. 2015 May;31(5):549-68. doi: 10.1016/j.cjca.2015.02.016. Review. PMID: 25936483.

--Rautureau Y, Coelho SC, Fraulob-Aquino JC, Huo K-G, Rehman A, Offermanns S, Paradis P, **Schiffrin EL**. Inducible human endothelin-1 overexpression in endothelium raises blood pressure via endothelin type

A receptors. *Hypertension*. 2015; 66:347-355. DOI: 10.1161/HYPERTENSIONAHA.115.05168. PMID: 2610134.

--Townsend R, Wilkinson I, **Schiffrin EL**, Avolio A, Bradley TJ, Chirinos JA, Cockcroft J, Ellison D, Heffernan K, Lakatta EG, McEniery C, Mitchell GF, Najjar S, Nichols W, Urbina E, Weber T; on behalf of the American Heart Association Council on Hypertension. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. A Scientific Statement of the American Heart Association. *Hypertension*. 2015;66:698-722. DOI: 10.1161/HYP.0000000000000033. PMID: 26160955

--Mian MOR, Barhoumi T, Briet M, Paradis P, **Schiffrin EL**. Deficiency of T regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. *J Hypertens* 2016, 34:97–108. DOI:10.1097/HJH.0000000000000761. PMID: 2663021.

--**Schiffrin EL**, Campbell NRC, Feldman RD, Kaczorowski J, Lewanczuk R, Padwal R, Tobe S. Hypertension in Canada: Past, Present and Future. *Ann Global Health*.

--**Schiffrin EL**. Mechanisms of remodelling of small arteries, antihypertensive therapy and the immune system in hypertension. *Clinical & Investigative Medicine*, [S.l.], p. E394-E402, dec. 2015. ISSN 1488-2353. Available at: <<http://cimonline.ca/index.php/cim/article/view/26202>>. Date accessed: 06 dec. 2015.

--**Schiffrin EL**, Calhoun D, Flack JM, Ito S, Webb RW. A message from the new editorial team at the American Journal of Hypertension. *Amer J Hypert*. 2016;29:1. doi:10.1093/ajh/hpv173

--**Schiffrin EL**, Calhoun D, Flack JM. SPRINT proves that lower is better for non diabetic high risk patients, but at a price. *Amer J Hypert*. 2016;29;2-4. doi:10.1093/ajh/hpv190. PMID: 26597221.

--Savoia C, **Schiffrin EL**. Vascular changes in the microcirculation: arterial remodeling and capillary rarefaction. Editors: Adel Berbari, Giuseppe Mancina. Springer International Publishing Switzerland 2015; pp 69-79. DOI 10.1007/978-3-31914556-3. ISBN 978-3-319-14556-3, © 2015

Schipper, Hyman M.

--Ravina B, Eberly S, Oakes D, Lang AE, Dodelet V, Roos P, Harman J, Shoulson I, **Schipper HM**. Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson disease –the SPIN-PD study. *Biomarkers Med* 9:89-97, 2015. [Also listed in NIR NEWS 26 (6): 19, 2015].

--Chen-Roetling J, Song W, **Schipper HM**, Christopher S, Regan CS, Regan RF. Astrocyte over expression of heme oxygenase-1 improves outcome after intracerebral hemorrhage. *Stroke* 46:00-00, 2015; DOI: 10.1161/STROKEAHA.115.008686.

--Lin S-H, Song W, Cressatti M, Zukor H, Wang E, **Schipper HM**. Heme oxygenase-1 modulates microRNA expression in cultured astroglia: Implications for chronic brain disorders. *GLIA* 63:1270–1284, 2015.

--**Schipper HM**, Arnold D, Grand’Maison F, Melmed C, Moore F, Levental M, Su H, Constantin M, Stril J-L, Godin J. Tolerability and safety of combined glatiramer acetate and N-acetylcysteine in relapsing-remitting multiple sclerosis. *ClinNeuropharmacol*38:127–131, 2015.

--Song W, Zukor H, Liberman A, Kaduri S, Arvanitakis Z, Bennett DA, **Schipper HM**. Astroglialheme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues. *World Biomed Front*, Dec 2014 <http://biomedfrontiers.org/alzheimer-2014-12-21>.

--**Schipper HM**. Is glial HO-1 suppression in neurodegenerative disorders permissive for neural repair? *Neural Regen Res* 10:208-210, 2015.

--**Schipper HM**, Song W. A heme oxygenase-1 transducer model of degenerative and developmental brain disorders. *Int J MolSci* 16, 5400-5419, 2015; doi:10.3390/ijms160354002015.

--Wang J, **Schipper HM**, Velly AM, Mohit S, Gornitsky M. Salivary biomarkers of oxidative stress: a critical review. *Free Rad Biol Med* 85:95–104, 2015.

--**Schipper HM**. The impact of gonadal hormones on the expression of human neurological disorders. *Neuroendocrinol* DOI: 10.1159/000440620 (2015).

--**Schipper HM**. Iron deposition in brain aging and disease. *Neuroscience and Biobehavioral Psychology*, in press (2015).

Schwartz, Blair

--**Schwartz BC**, Frenette C, Lee TC, Green L, Jayaraman D. (2015) Novel low resource intervention reduces urinary catheter use and associated urinary tract infections: role of outcome measure bias? *Am J Infect Control* 43(4):348-53

Sebag, Igal

--Mylotte D, Andalib A, Thériault-Lauzier P, Dorfmeister M, Girgis M, Alharbi W, Chetrit M, Galatas C, Mamane S, **Sebag I**, Buithieu J, Bilodeau L, de Varennes B, Lachapelle K, Lange R, Martucci G, Virmani R, Piazza N. Transcatheter heart valve failure: a systematic review. *Eur Heart J*. 2015;36:1306-27.

--Tan TC, Bouras S, Sawaya H, **Sebag IA**, Cohen V, Picard MH, Passeri J, Kuter I, Scherrer-Crosbie M. Time trends of left ventricular ejection fraction and myocardial deformation indices in a cohort of women with breast cancer treated with anthracyclines, taxanes and trastuzumab. *J Am Soc Echocardiogr* 2015;28:509-14.

--Putt M, Hahn VS, Sawaya H, Januzzi JL, **Sebag IA**, Plana JC, Picard MH, Gerszten RE, Halpern EK, Kuter I, Martin RP, Carver JR, Scherrer-Crosbie M, Ky B. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes and trastuzumab. Accepted for publication in *Clinical Chemistry* 2015.

--Patel B, Raad M. **Sebag IA**, **Chalifour L**. Sex-specific cardiovascular responses to control or high fat diet feeding in C57bl/6 mice chronically exposed to bisphenol A. *Toxicology Reports* 2: 1310-1318, 2015

Sheppard, Richard

--Goldfarb M, **Sheppard R**, Afilalo J. Prognostic and Therapeutic Implications of Frailty in Older Adults with Heart Failure. *Curr Cardiol Rep*. 2015 Nov;17(11):92. doi: 10.1007/s11886-015-0651-3. PubMed PMID: 26346250.

Small, David

--Ma K, **Cohen V**, Kasymjanova G, **Small D**, Novac K, Peterson J, Levit A, Agulnik J: An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre. *Current oncology* (Toronto, Ont 2015, 22(3):e157-163.

Suissa, Samy

- Suissa S**, Ernst P. Long-acting B-agonists with vs without inhaled corticosteroids for COPD. *JAMA*. 2015 Jan 20;313(3):305
- Curtis JR, Perez-Gutthann S, **Suissa S**, Napalkov P, Singh N, Thompson L, Porter-Brown B; Actemra Pharmacoevidence Board. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large post-marketing data set from multiple data sources. *Semin Arthritis Rheum*. 2015 Feb;44(4):381-8
- Fournier JP*, Azoulay L, **Yin H**, Montastruc JL, **Suissa S**. Tramadol use and the risk of hospitalization for hypoglycemia in patients with non-cancer pain. *JAMA Internal Medicine*. 2015 Feb 1;175(2):186-93
- Lapi F*, Azoulay L, Kezouh A, Benisty J, Matok I, Mugelli A, **Suissa S**. The use of antidepressants and the risk of chronic atrial fibrillation. *J Clin Pharmacol* 2015 Apr;55(4):423-30
- Suissa S**. Number needed to treat: enigmatic results for exacerbations in COPD. *Eur Respir J* 2015 Apr;45(4):875-8
- Faillie JL*, **Suissa S**. Immortal time bias in pharmacoepidemiological studies: Definition, solutions and examples. *Therapie*. 2015 Mai-Juin;70(3):259-63
- Suissa S**, Ernst P. The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis. *Thorax*. 2015 May;70(5):508-10
- Suissa S**. The Quasi-cohort approach in pharmacoepidemiology: upgrading the nested case-control. *Epidemiology*. 2015 Mar;26(2):242-6
- Fournier JP*, Wilchesky M, Patenaude V, **Suissa S**. Concurrent use of benzodiazepines and antidepressants and the risk of motor vehicle accident in older drivers: a nested case-control study. *Neurology and Therapy* 2015 June;4(1):39-51
- Suissa S**. The number needed to treat: 25 years of trials and tribulations in clinical research. *Rambam Maimonides Med J*. 2015 Jul 30;6(3)
- Simon TA, Thompson A, Gandhi KK, Hochberg MC, **Suissa S**. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. *Arthritis Res Ther*. 2015 Aug 15;17(1):212
- Targownik L. **Suissa S** et al. Understanding and avoiding immortal-time bias in gastrointestinal observational research. *Am J Gastroenterol* 2015 Sept (epub ahead of print)
- Bitton A, Vutcovici M, Sewitch M, **Suissa S**, Brassard P. Mortality trends in crohn's disease and ulcerative colitis: a population-based study in Quebec, Canada. *Inflamm Bowel Dis* 2015 Oct (epub ahead of print)
- Suissa S**, Rossi A. Weaning from the inhaled corticosteroids in COPD: the evidence. *Eur Respir J*. 2015 Nov;46(5):1232-35
- Suissa S**, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. *Chest*. 2015;148(5):1177-1183
- Tran T, Brophy JM, **Suissa S**, Renoux C. Risks of cardiac valve regurgitation and heart failure associated with ergot-and non-ergot-derived dopamine agonist use in patients with Parkinson's disease : A systematic review of observational studies. *CNS Drugs* November 2015 (e-pub ahead of print)

Szilagyi, Andrew

--**Szilagyi, A.** Adult lactose digestion status and effects on disease. *Can J Gastroenterol Hepatol.* 2015; 29:149-56. (IF 1.96)

--**Szilagyi, A.** Adaptation to Lactose in Lactase Non Persistent People: Effects on Intolerance and the Relationship between Dairy Food Consumption and Evaluation of Diseases. *Nutrients* 2015, 7, 6751-6779. (IF 3.27)

Tagalakis, Vicky

--Carrier M, Lazo-Langner A, Shivakumar S, **Tagalakis V**, Zarychanski R, Solymoss S, Routhier N, Douketis J, Danovitch K, Lee AY, Le Gal G, Wells PS, Corsi DJ, Ramsay T, Coyle D, Chagnon I, Kassam Z, Tao H, Rodger MA; SOME Investigators. Screening for occult cancer in unprovoked venous thromboembolism. *The New England Journal of Medicine* 2015. [Epub ahead of print]

--Easaw JC, Shea-Budgell MA, Wu CMJ, Czaykowski PM, Kassis J, Kuehl B, Lim HJ, MacNeil M, Martinusen D, McFarlane PA, Meek E, Moodley O, Shivakumar S, **Tagalakis V**, Welch S, Kavan P. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. *Current Oncology* 2015; 22(2):144-155

--Easaw JC, Shea-Budgell MA, Wu CMJ, Czaykowski PM, Kassis J, Kuehl B, Lim HJ, MacNeil M, Martinusen D, McFarlane PA, Meek E, Moodley O, Shivakumar S, **Tagalakis V**, Welch S, Kavan P. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. *Current Oncology* 2015; 22(2):133-143

--Klil-Drori A, Yin H, **Tagalakis V**, Aprikian A, Azoulay L. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. *European Urology* 2015. [Epub ahead of print]

--Leung Yinko SS, Pelletier R, Behloul H, Bacon SL, Karp I, Thanassoulis G, Daskalopoulou SS, Eisenberg MJ, Khan NA, Lavoie KL, Pilote L; GENESIS-PRAXY investigators (**Tagalakis V**). Potential factors associated with fruit and vegetable intake after premature acute coronary syndrome: a prospective cohort study. *International Journal of Food Sciences and Nutrition* 2015; 1-7 [Epub ahead of print]

--Rabinovich A, Cohen JM, Cushman M, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, **Tagalakis V**, Lazo-Langner A, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Ginsberg JS, Kahn SR. Inflammation Markers and Their Trajectories after Deep Vein Thrombosis in relation to Risk of Postthrombotic Syndrome. *Journal of Thrombosis and Haemostasis* 2015; 13(3):398-408

Trifiro, Mark

--Schweitzer M, Makhoul S, Paliouras M, Beitel LK, Gottlieb B, **Trifiro M**, Chowdhury S, Zaman N, Wang E, Davis H, Chalifour LE. (2015). Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe. *Atherosclerosis.* 24(246): 78-86.

--Dotan I, Roche PJR, Paliouras M, Mitmaker EJ, **Trifiro MA.** (2015). Engineering Multi-walled Carbon Nanotube Therapeutic Bionano fluids to Selectively Target Papillary Thyroid Cancer Cells. *PloSOne.* 2015: 1-10.14

--Carnevale ML, Roche PJR, Najih M, Paliouras M, Beitel LK, **Trifiro MA.** (2015). A rapid diagnostic method for *E. coli* serogroups responsible for gastro-intestinal diseases using loop-mediated isothermal amplification. *Analytical Methods.* 7(1): 287-295.

Trudeau, Luc

--Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, **Trudeau L** et al for the Canadian Hypertension Education Program. The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. *Can J Cardiol.* (2015) 31:549-568.

--Johnson C, Thout SR, **Trudeau L**, Bacon SL, Padwal RS, Webster J, Campbell N. The Science of Salt: A Systematic Review of Clinical Salt Studies 2013 to 2014, *Journal of Clinical Hypertension.* (2015) 17:5:401–411

--Padwal RS, Townsend RR, **Trudeau L**, Hamilton PG, Gelfer M. Comparison of an in-pharmacy automated blood pressure kiosk to daytime ambulatory blood pressure in hypertensive subjects. (2015) 9:2:123–129

Vedel, Isabelle

--Khanassov V*, **Vedel I**. Family physician – case manager collaboration and needs of patients with dementia and their caregivers: A systematic mixed studies review. Accepted, *Annals of Family Medicine*

--Pluye P, Hong QN, Bush P, **Vedel I**. The plurality of review methods and synthesis methods. Accepted, *Journal of Clinical Epidemiology*

--**Vedel I**, Khanassov V*. Transitional care for patients with congestive heart failure: A systematic review and meta-analysis. *Annals of Family Medicine* 2015;13:562-571.

--Bergman S, Al-Bader M, Sourial N, **Vedel I**, Hanna WC, Bilek AJ, Galatas C, Marek JE, Fraser SA. Recurrence of biliary disease following non-operative management in elderly patients. *Surg Endosc.* 2015 Feb 12. [Epub ahead of print]

--Souto R, Khanassov V*, Hong QN, Bush PL, **Vedel I**, Pluye P. Systematic mixed studies reviews: updating results on the reliability and efficiency of the mixed methods appraisal tool. *International Journal of Nursing Studies* 2015;52(1):500-501. DOI:<http://dx.doi.org/10.1016/j.ijnurstu.2014.08.010>

Wainberg, Mark

--Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, **Wainberg MA**, Roger M. Evolution of a novel pathway leading to dolutegravir resistance in a patient harboring N155H and multiclass drug resistance. *Antimicrobial Chemotherapy* 2015;70(2):405-11.

--Kramer V, Hassounah S, Colby-Germinario S, Oliveira M, Lefebvre E, Mesplede T, **Wainberg MA**. The dual CCR5 and CCR2 inhibitor Cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. *Journal of Antimicrobial Chemotherapy.* 2015; 70(3):750-756.

--Cutillas V, Mesplede T, Anstett K, Hassounah S, **Wainberg MA**. The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against Dolutegravir. *Antimicrobial Agents & Chemotherapy* 2015. 59(1):310-316

--Quashie PK, OlivieraM, Veres T, Osman N, Han YS, Hassounah S, Lie Y, Huang W, Mesplède T, and **Wainberg MA**. Differential effects of the G118R, H51Y and E138K resistance substitutions in different subtypes of HIV integrase. *J. Virol*2015. 89(6):3163-75

--Anstett K, Mesplede T, Oliveira M, Cutillas V, and **Wainberg MA**. The Dolutegravir-Resistance Mutation R263K Cannot Co-Exist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions. *J. Virol* 2015.89(8)4681-4684

--Wares M., Hassounah S, Mesplède T, Sandstrom PA, **Wainberg MA**. Simian-tropic HIV as a model to study drug resistance against integrase inhibitors. *Antimicrob Agents Chemother.* 2015;59(4):1942-9.

--Zhu W, Lei R, Le Duff Y, Li J, Guo F, **Wainberg MA**, and Liang C. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. *Retrovirology* 2015;12(1):22.

--Depatureaux A, LeBlanc R, Moisi D, Brenner B, and **Wainberg MA**. The first report of HIV-1 group O infection in Canada. *J Infect Dis Ther* 2015. 3:1

--Xu HT, Colby-Germinario SP, Quashie PK, Bethell R, and **Wainberg MA**. Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor. *Antimicrobial Agents & Chemotherapy* 2015. 59(6):3189-96

--Campos N, Myburgh R, Garcel A, Vautrin A, Lapasset L, Nadal ES, Mahuteau F, Najman R, Fornarelli P, Tantale K, Basyuk E, Séveno M, Venables JP, Pau B, Bertrand E, **Wainberg MA**, Speck R, Scherrer D and Tazi J. Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis. *Retrovirology* 2015. 12:30

--Han Y-S, Xiao W-L, Xu HT, Kramer VG, Quan Y, Mesplède T, Oliveira M, Colby-Germinario SP, Sun HD, and **Wainberg MA**. Identification of a dibenzocyclooctadienelignan as a HIV-1 non nucleoside reverse transcriptase inhibitor. *Antiviral Chemistry & Chemotherapy* 2015. 24(1)28-39.

--Mesplede T, Moisi D, Oliveira M, Ibanescu I, Ohnona F, Brenner B, **Wainberg MA**. Dolutegravir inhibits HIV-1 Env evolution in primary human cells. *AIDS* 2015. 29(6):659-65

--Singhroy DN, **Wainberg MA**, and Mesplede T. The combination of the R263K and M184I/V resistance mutations against dolutegravir and lamivudine decreases HIV viral fitness. *Antimicrob. Agents Chemother* 2015. 59(5)2882-2885

--Zhang H, Han Y, **Wainberg MA**, Yue JM. Anti-HIV Securinega alkaloid oligomers from *Flueggea virosa*. *Tetrahedron* 2015. 71, 3671-3679

--Quashie PK, Han YS, Hassounah S, Mesplede T, and **Wainberg MA**. Structural studies of the HIV-1 integrase protein: Compound screening and characterization of a DNA-binding inhibitor. *PLOS ONE* 2015 10(6):e0128310.

--Mesplede T, and **Wainberg MA**. Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. *Viruses* 2015.7(7): 3703–3718.

--Depatureaux A, Mesplede T, Quashie P, Oliveira M, Moisi D, Plantier JC, Brenner B, **Wainberg MA**. HIV-1 group O resistance against integrase inhibitors. *J Acquir Immune Defic Syndr.* 2015;70(1):9-15.

--Isitman G, Lisovsky I, Tremblay-McLean A, Parsons MS, Shoukry NH, **Wainberg MA**, Bruneau J, Bernard NF. NK cell education does not affect the magnitude of granzyme B delivery to target cells by antibody dependent cellular cytotoxicity. *AIDS* 2015, 29:1433-1443

--Mesplède T, Quashie PK, Hassounah S, Osman N, Han Y, Liang J, Singhroy DN, and **Wainberg MA**. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. *AIDS* 2015. 29:1459-1466.

--Yu JH, Wang GC, Han Y, Wu Y, **Wainberg MA**, and Yue JM. Limonoids with Anti-HIV Activity from *Cipadessacinerascens*. *Journal of Natural Products*. 2015. 78(6):1243-52

--Osman N, Mesplede T, Quashie P, Oliveira M, Zanichelli V, **Wainberg MA**. Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. *Journal of Antimicrobial Chemotherapy* 2015. 70(10):2810-5.

--Anstett K, Fusco R, Cutillas V, Mesplede T, and **Wainberg MA**. Dolutegravir-selected HIV-1 containing the N155H/R263K resistance substitutions does not acquire additional compensatory mutations under drug pressure that lead to higher level resistance and increased replicative capacity. *J. Virol.* 2015. 89(8): 4681–4684

--Oliveira M, Mesplede T, Moisi D, Ibanescu IR, Brenner BG, and **Wainberg MA**. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir. *AIDS* 2015.29:2255-2260

--Liang J, Mesplède T, Oliveira M, Anstett K, and **Wainberg MA**. The combination of the R263K and T66I resistance substitutions in HIV-1 integrase is incompatible with high level viral replication and the development of high-level drug resistance. *J. Virol* 2015. 89(22):11269-74.

--Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Preau M, Rooney JF, **Wainberg MA**, Thompson D, Rozenbaum W, Dore V, Marchant L, Simon MC, Etien N, Aboulker JP, Meyer L, et Delfraissy JF. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. *New England Journal of Medicine* 2015.373(23):2237-46.

--Hassounah SA, Liu Y, Quashie PK, Oliveira M, Moisi D, Brenner BG, Sandstrom PA, Mesplede T, and **Wainberg MA**. Characterization of the drug resistance profiles of integrase strand transfer inhibitors in SIVmac239. *J. Virol* 2015.89(23):12002-13.

--Han YS, Quashie PK, Mesplède T, Xu H, Quan Y, Jaeger W, Szekeres T, and **Wainberg MA**. A Resveratrol Analog Termed 3,3',4,4',5,5'-Hexahydroxy-trans-Stilbene Is A Potent HIV-1 Inhibitor. *J Med Virol* 2015. 87(12):2054-60.

--Yue J-M, Zhang H, Zhu KK, Han YS, Luo C, **Wainberg MA**. Flueggeather A and virosinine A, anti-HIV alkaloids from flueggeavirsa. *Organic Letters* 2015. 17(24):6274-7.

--Rhee SH, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zy GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndambi N, Hamers RL, Rinke de Wit TB, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AMJ, Gallant JE, **Wainberg MA**, Richman DD, 29, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, and Shafer RW. HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. *PLOS One* 2015. 10(12): e0145772. doi:10.1371/journal.pone.0145772

--Kramer VG, **Wainberg MA**. Resistance against Inhibitors of HIV-1 Entry into Target Cells. *Future Virology* 2015, 10(2), 97-112.

--**Wainberg MA**, and Mesplede T. Is drug resistance in first-line therapy against all antiretroviral agents inevitable? *J. Infect. Dis. Ther.* 2015, 3:2

--**Wainberg MA**, Han YS. Will drug resistance against dolutegravir in initial therapy ever occur? Review article *Frontiers in Pharmacology*. Volume 6. Article 90.

--Kramer V.G., and **Wainberg MA**. HIV-1 entry inhibitor resistance. *Handbook of Antimicrobial Resistance*. In Springer Science & Business Media, New York 2014

--**Wainberg MA** and Han YS. HIV-1 resistance to dolutegravir: update and new insights. *Journal of Virus Eradication* 2015; 1:13-16

--Sluis-Cremer N, **Wainberg MA**, Schinazi JF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. *Future Microbiology* (accepted for publication)

--**Wainberg MA**, Kippax S, Bras M, Sow PS. Has the world ceased to care about HIV? And what can we do about it? *J Int AIDS Soc.* 2015; 18(1): 20818

--**Wainberg MA**, Mesplede T. Implications for the Future of the HIV Epidemic if Drug Resistance against Dolutegravir Cannot Occur in First-Line Therapy. *J Int AIDS Soc.* 2015; 18(1): 20824.

--Lever A, **Wainberg MA**. World AIDS day 2015. *Retrovirology*. 2015; 12: 101.

--Han Y, Mesplede T, and **Wainberg MA**. Cabotegravir. *Drugs of the Future* 2015, 40(11):705-715

Wolkove, Norman

--Dajczman E, Wardini R, Kasymjanova G, Préfontaine D, Baltzan MA, **Wolkove N**. Six minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation. *Canadian Respiratory Journal*. 2015;22(4):225 - 229

Wyse, Jonathan

--Bhat M, **Wyse JM**, Moodie E, Ghali P, **Hilzenrat N**, Wong P and Deschenes M. Prevalence and predictors of sleep disturbance among liver diseases in long-term transplant survivors. *Canadian Journal of Gastroenterology* 2015; 29: 440-444

Yu, Oriana

--**Yu OH**, Yin H, and Azoulay L. The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death. *39(5):383-9; 2015*

--**Yu OH**, Filion KB, Azoulay L, Patenaude V, Majdan A, Suissa S. Incretin-based drugs and the risk of congestive heart failure. *Diabetes Care*. 2015; 38:277-84

7. APPENDIX A. DIVISIONAL REPORTS